

REGENERATIVE MEDICINE & PERIPHERAL NERVE ENDOSCOPY

Editors:

Kai-Uwe Lewandrowski

William Omar Contreras López

Jorge Felipe Ramírez León

Álvaro Dowling

Morgan P. Lorio

Bentham Books



**Neuroendoscopy and
Interventional Pain Medicine**
(Volume 1)

***Regenerative Medicine &
Peripheral Nerve Endoscopy***

Edited by

Kai-Uwe Lewandrowski

*Center for Advanced Spine Care of Southern Arizona and
Surgical Institute of Tucson. Tucson, AZ, USA*

William Omar Contreras López

*Clínica Foscal Internacional
Autopista Floridablanca - Girón, Km 7, Floridablanca
Santander, Colombia*

Jorge Felipe Ramírez León

*Fundación Universitaria Sanitas
Bogotá, D.C., Colombia*

Álvaro Dowling

*Orthopaedic Spine Surgeon, Director of Endoscopic Spine
Clinic'Santiago, Chile*

&

Morgan P. Lorio

*Advanced Orthopedics, 499 East Central Parkway
Altamonte Springs, FL 32701, USA*

Assistant Editors

Hui-lin Yang

*Professor & Chairman of Orthopedic Department
The First Affiliated Hospital of Soochow University
No. 899 Pinghai Road, Suzhou, China*

Xifeng Zhang

*Department of Orthopedics, Wangjing Hospital
China Academy of Chinese Medical Sciences, Beijing, China*

&

Anthony T. Yeung

*Desert Institute for Spine Care
Phoenix, AZ, USA*

Neuroendoscopy and Interventional Pain Medicines

(Volume 1)

Regenerative Medicine & Peripheral Nerve Endoscopy

Editors: Kai-Uwe Lewandrowski, William Omar Contreras López,

Jorge Felipe Ramírez León, Álvaro Dowling & Morgan P. Lorio

ISSN (Online): 52: 4/: 3: Z

ISSN (Print): 52: 4/: 393

ISBN (Online): 978-981-5274-46-2

ISBN (Print): 978-981-5274-47-9

ISBN (Paperback): 978-981-5274-48-6

© 2024, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2024.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



ENDORSEMENTS

SICCM I (Sociedad Interamericana Cirurgia de Columna Minimamente Invasiva)



Founded in 2006, SICCM I aims to advance and mainstream minimally invasive spine surgery (MIS), aligning with the objectives of Neuroendoscopy & Interventional Pain Medicine. Our members have worked to implement MIS throughout South America, the Caribbean, Central America, and North America. Many of our key opinion leaders perform endoscopic surgery at the highest level and have contributed to this comprehensive multi-volume text. Four of the editors hold leadership positions within SICCM I. The table of contents is extensive, covering the cervical and lumbar spine and advanced technological applications. This book will serve as the core curriculum and course material for endoscopic spine surgery within SICCM I. It is my pleasure to endorse it on behalf of our society.

Alvaro Dowling

Past President of SICCM I

ISASS



The origins of the International Society for the Advancement of Spine Surgery (ISASS), formerly known as The Spine Arthroplasty Society, can be traced back to its focus on motion preservation as an alternative approach to fusion. Over time, ISASS has remained dedicated to its overarching mission of serving as a worldwide hub for scientific exploration and education, centered around the needs of surgeons.

ISASS was established with the primary goal of creating an impartial platform where experts could openly discuss and tackle various aspects of both fundamental and clinical research related to motion preservation, stabilization, cutting-edge technologies, minimally invasive procedures, biologics, and other crucial subjects aimed at restoring and enhancing spinal motion and function. The society boasts a diverse and thriving global membership consisting of orthopedic and neurosurgery spine surgeons as well as scientists.

ISASS stands committed to pushing the boundaries of spinal techniques and procedures, including groundbreaking approaches like endoscopic spine surgery. A testament to this dedication is this text, *Neuro-endoscopy*, which serves as a reservoir of knowledge contributed by experts, resulting in a comprehensive and current reference text. This publication stands as a tangible example of our unwavering commitment to surgeon education and scientific advancement.

As representatives of ISASS, we take great pleasure in endorsing this all-encompassing text. It is a true reflection of our society's tireless pursuit of enhancing surgical education and promoting rigorous scientific exploration.

International Society for the Advancement of Spine – forging ahead on the path of progress.

Huilin-Lin Yang MD, PhD

ISASS Co-President, International 2023-2024

Morgan P. Lorio MD, FACS

Co-President Elect, USA 2024-2025

DR. KAI-UWE LEWANDROWSKI
AMCICO ENDORSEMENT
Neuroendoscopy and Interventional Pain
Medicine



Asociación Mexicana de
Cirujanos de Columna A.C.

Dear Dr. Lewandrowski:

On behalf of the board of Asociación Mexicana de Cirujanos de Columna A.C (AMCICO) it's an honor to endorse your upcoming groundbreaking text entitled *Neuroendoscopy and Interventional Pain Medicine*.

Your editors and authors highlighted the advancement and mainstreaming of minimally invasive surgery (MIS) for various topics in neurosurgery, spine surgery, and novel interventional pain management strategies involving the endoscopic technology platform. AMCICO members recently joined to discuss the implementation of MIS endoscopic surgery techniques in Mexico, where many of its key opinion leaders, some of whom have contributed to this outstanding text, perform endoscopic surgery at the highest level. The book content is exhaustive and comprehensive, encompassing cervical and lumbar spine topics with advanced technology applications. Moreover, your text highlights endoscopic surgery techniques of the cranium and skull base and, for the first time, describes the prenatal intra-uterine endoscopic repair of spina bifida. Neuroendoscopy and Interventional Pain Medicine will serve as AMCICO's core curriculum and course material for endoscopic surgery of the spine and neurological system. It is my pleasure to endorse it on behalf of AMCICO.

Again, we thank you for your valuable academic contribution and reiterate our disposition to assist with disseminating your outstanding text.

Sincerely

Dr. Eulalio Elizalde Martinez

President of AMCICO

Junta Directiva 2021 - 2023



Dr. Jaime Moyano
Presidente

Dr. José Antonio Soriano
1er Vicepresidente

Dr. Paulo Pereira
2do Vicepresidente

Dr. José Gabriel Rugeles
Secretario

Dr. Álvaro Rocchietti
Tesorero

Dr. Hani Mhaidli
Presidente Anterior

Comisión Científica

Dr. Jorge Alves
Dr. Juan P. Bernasconi
Dr. Nicolás Galli
Dr. Mario Herrera
Dr. Ratko Yurac
Dr. Juan José Jara
Dr. Antonio Martín B.
Dr. Robert Meves

Comisión Fiscal

Dr. Eugenio Galilea
Dr. Alberto Diez Ulloa
Dr. Luis Miguel Duchén
Dr. Roberto Muscia

SILACO (Sociedad Ibero Latinoamericana de Columna) had its beginnings in the meetings of the Scoliosis Research Society with the first Hispano-American Congress held in 1991 in Buenos Aires Argentina.

Since then, it has morphed into an organization that promotes the study of treatments and prevention of spinal conditions by bringing together spine care professionals from all subspecialties.

The scientific activities of our biannual Ibero-Latin American Congress are focused on the promotion of surgeon education to the highest academic standards via international relationships between members from the Americas, Spain and Portugal.

Neuroendoscopy and interventional Pain Management resembles such a collaborative effort where authors worldwide have come together to update the reader on the latest endoscopic spinal surgery techniques.

SILACO has incorporated Neuroendoscopy and interventional Pain Management into its core curriculum and plans on using it as course material for its continuing education courses.

It is my pleasure to endorse it on behalf of SILACO.

Dr. Jaime Moyano
President of SILACO

Editor SEOT Magazine

Ecuadorian Society of Orthopedics and Traumatology – SEOT

SOMEEC - Sociedad Mexicana de Endoscopia de Columna



SOMEEC - Sociedad Mexicana de Endoscopia de Columna – is Mexico’s prime organization uniting spine surgeons with diverse training backgrounds who have a fundamental interest in endoscopic surgery. SOMEEC organizes annual meetings where member surgeons and international faculty update each other on their latest clinical research to promote spine care via endoscopic spinal surgery techniques. Two of the senior lead editors of Neuroendoscopy & Interventional Pain Medicine have been active international supporters of SOMEEC. I am pleased to endorse their latest three-volume reference text, Neuroendoscopy & Interventional Pain Medicine which will become an integral centerpiece of SOMEEC’s continuing medical education programs.

Enrique Saldívar Farrera

President of the Sociedad Mexicana de Endoscopia de Columna

Roberto Cantu, Jr. MD

Vice President of the Sociedad Mexicana de Endoscopia de Columna

Academia Nacional de Medicina de Colombia

The Academia Nacional de Medicina de Colombia recognizes the high academic and scientific value of the comprehensive three-volume text *Neuroendoscopy & Interventional Pain Medicine*, developed by leading figures in the field—including our esteemed members of our Academy, Dr. Kai-Uwe Lewandrowski, William Omar Contreras, and Dr. Jorge Felipe Ramirez—represents a significant advancement in minimally invasive spinal surgery. It will undoubtedly serve as an essential resource for both current and future spine specialists, greatly enhancing clinical practice and patient outcomes.

Gabriel Carrasquilla MD, DrPH, MPH, MSc

President, Academia Nacional de Medicina de Colombia

**Asociación Colombiana de Neurocirugía
(ACNCx)**



The Asociación Colombiana de Neurocirugía (ACNCx) is a non-profit, private legal entity dedicated to promoting the scientific and ethical development of neurosurgery in Colombia. Established in 1962, ACNCx is committed to advancing professional responsibility, continuous improvement, and the highest standards of patient care. ACNCx operates with a democratic structure, upholding principles of solidarity, unity, and participation. Our association is deeply involved in the education and advancement of neurosurgical practices, including innovative procedures such as prenatal endoscopic repair and endoscopic interventions for the brain, neuroaxis, and spine.

It is with great pleasure that I endorse Neuroendoscopy & Interventional Pain Medicine on behalf of ACNCx. This book highlights the groundbreaking work of Colombian authors and serves as a valuable resource for our members and the broader neurosurgical community.

Best Regards,

Alberto Dau Acosta

President

Colombian Association of Neurosurgery

International Society for Minimally Invasive Spine Surgery (ISMIS)



The International Society for Minimal Intervention in Spine Surgery (ISMIS) brings together spine surgeons from all over the world united by the constant strive for advances in minimally invasive techniques. Since its conception in 1988 on the occasion of the GIEDA-Bruxelles meeting, international coordination of educational, instructional, and scientific exchanges in minimally invasive spine surgery has been the highest priority for prior and current directories.

As the newly elected president of ISMIS, it is my great pleasure to endorse Neuroendoscopy & Interventional Pain Medicine as an extraordinary textbook of up-to-date collaborative expertise in endoscopic techniques of the spine and neuroaxis. I am convinced that it will contribute significantly to the educational process of future spine specialists.

Prof. Dr. Joachim Oertel

President ISMIS

Chinese Orthopaedic Association (COA)



Chinese Orthopaedic Association (COA), a specialty society within Chinese Medical Association, was founded in 1980. It aims to promote scientific exchange, provide orthopaedic education, and improve patient care. COA is the largest and most influential orthopaedic society in China, equivalent to AAOS in the US. Its annual meetings attract about 15,000-32000 attendees, including world-class experts, presidents of international orthopaedic societies, and leaders from national orthopaedic associations.

In line with its mission to foster global discussions and enhance surgeon education, it is my pleasure as Chairman of the COA MISS Society to endorse Neuroendoscopy & Interventional Pain Medicine. This comprehensive text, created by an international team of editors and contributors, including many from China, provides an expert update on the latest endoscopic spinal surgery techniques.

I am confident that this book will become an essential part of any reputable spine surgeon society's core curriculum and serve as valuable course material for continuing education programs. It is my honor to support Neuroendoscopy & Interventional Pain Medicine on behalf of the COA MISS Society.

Huilin Yang

Professor Huilin Yang

Chairman of COA MISS Society

Japanese Minimally Invasive Spine Surgery Society (JASMISS)



As JASMISS president I am interested in discussing advancements in surgical techniques, and collaborate on clinical trials. Through these initiatives, we continue to foster a collaborative environment that supports the continuous improvement and adoption of minimally invasive techniques in spine surgery.


This dedication to excellence is evident in Neuroendoscopy & Interventional Pain Medicine, which features numerous contributions from Asian authors showcasing their groundbreaking work. It is my pleasure to endorse Neuroendoscopy & Interventional Pain Medicine.

Professor Koichi Sairyo, MD, PhD

President of the Japanese Society of Minimally Invasive Spine Surgery (JASMISS)

Tokushima University, Japan.

Korean Research Society of Endoscopic Spine Surgery (KOSESS)



Founded in 2017, the Korean Research Society of Endoscopic Spine Surgery (KOSESS) aims to unite endoscopic spine surgeons in the Republic of Korea to advance the subspecialty through high-quality clinical research. This dedication to excellence is evident in Neuroendoscopy & Interventional Pain Medicine, which features numerous contributions from Korean authors showcasing their groundbreaking work.

It is my pleasure to endorse Neuroendoscopy & Interventional Pain Medicine on behalf of KOSESS.

Chang-il Ju M.D.,Ph.D.

President of KOSESS

Professor

Department of Neurosurgery

Chosun University Hospital

Gwangju, Korea

H.P. 010-3666-4100

Sociedade Brasileira de Coluna (SBC)



Founded on October 12, 1994, the Brazilian Spine Society (Sociedade Brasileira de Coluna - SBC) is a scientific, non-profit organization dedicated to advancing spine surgery through basic research and clinical studies in Orthopedics and Neurosurgery. SBC is committed to the accreditation and continued education of spine surgeons in Brazil, providing its members with access to the latest scientific evidence and technological advancements in spine care. Through its monthly publication, *Columna*, and various online courses, including an Introduction to Endoscopy, SBC strives to keep its members at the forefront of the field.

The editors of *Neuroendoscopy & Interventional Pain Medicine* have created a comprehensive reference text that is essential to SBC's core curriculum for teaching endoscopy of the spine and neuroaxis. This book presents validated clinical protocols for the endoscopic treatment of cervical and lumbar spine conditions, backed by peer-reviewed articles from its contributors.

It is my pleasure to endorse *Neuroendoscopy & Interventional Pain Medicine* on behalf of the Brazilian Spine Society. This work will undoubtedly play a crucial role in educating the next generation of spine surgeons in Brazil.

Dr. Robert Meves

President of SBC

Sociedad Colombiana De Cirugía Ortopedia Y Traumatología (SCCOT)



The Sociedad Colombiana de Cirugía Ortopedia y Traumatología (SCCOT) is a non-profit, autonomous, scientific organization committed to enhancing spine care and surgery for orthopaedic and neurosurgeons, as well as other healthcare professionals in Colombia. Established to foster collaboration and innovation, SCCOT unites specialists with diverse scientific interests and expertise. Our goal is to promote continuous professional development and education, ensuring our members are well-versed in the latest advancements in spinal care.

With great enthusiasm, on behalf of SCCOT, endorse the three-volume book series Neuroendoscopy & Interventional Pain Management. This text is of significant interest to SCCOT due to its advanced technological applications and comprehensive discussion of validated clinical protocols for endoscopic spinal surgery and neuroaxis interventions.

The editors of this landmark series are esteemed leaders in minimally invasive spine surgery. Their combined expertise and dedication to advancing the field are evident throughout the volumes, making this series an invaluable resource for spine surgeons and related professionals.

Neuroendoscopy & Interventional Pain Management will serve as a cornerstone for SCCOT's continuing medical education programs. The extensive table of contents covers crucial topics related to the cervical and lumbar spine, as well as the latest technological advancements. This series will undoubtedly become a vital part of our educational initiatives, equipping our members with the knowledge and tools to excel in their practice.

I am honored to endorse this significant work on behalf of SCCOT. The dedication and expertise of the editors have produced a reference text that will shape the future of spine surgery and improve patient care worldwide.

Dr. William Arbeláez Arbeláez

President Sociedad Colombiana de Cirugía Ortopedia y Traumatología (SCCOT)

**Sociedad Latinoamericana de Ortopedia y
Traumatología (SLAOT) / Latin American
Society of Orthopaedics and Traumatology**



The Sociedad Latinoamericana de Ortopedia y Traumatología (SLAOT) is a non-profit, autonomous, scientific organization dedicated to orthopaedic surgeons and care professionals. SLAOT unites experts with diverse scientific interests, promoting continuous professional development and education at the highest level.

Neuroendoscopy & Interventional Pain Management is highly relevant to SLAOT due to its exemplary use of advanced technology and detailed discussion of validated clinical endoscopic spinal surgery protocols. It is my pleasure to endorse this comprehensive text on behalf of SLAOT.

Dr. Victor Naula

President of SLAOT FEDERACION



Academia Nacional de Medicina

Av. General Justo, 365 – 7º andar - Centro - Rio de Janeiro - RJ

www.anm.org.br

Diretoria Biênio 2024-2025

Presidente

Eliete Bouskela

1º Vice-Presidente

Antonio Egidio Nardi

2º Vice-Presidente

Ronaldo Damião

Secretário Geral

Omar Lupi da Rosa Santos

1º Secretário

Mônica Roberto Gadelha

2º Secretário

José Hermógenes Rocco Suassuna

Tesoureiro

Henrique Murad

1º Tesoureiro

Rossano Kepler Alvim Fiorelli

Orador

Natalino Salgado Filho

Diretor de Biblioteca

Jayme Brandão de Marsillac

Diretor de Arquivo

Miguel Carlos Riella

Diretor de Museu

Arno von Buettner Ristow

Presidente da Seção de Medicina

José Galvão-Alves

Presidente da Seção de Cirurgia

José de Jesus Peixoto Camargo

Presidente da Seção de Ciências Aplicadas à Medicina

Walter Araújo Zin

Rio de Janeiro, August 22, 2024

Commendation of *Neuroendoscopy & Interventional Pain Medicine*

The Academia Nacional de Medicina de Brazil remains steadfast in its commitment to advancing medical knowledge, fostering education, and upholding the highest standards in patient care. It is with great honor that we commend Dr. Kai-Uwe Lewandrowski, one of our esteemed members, and his team of leading experts for their exemplary work in producing *Neuroendoscopy & Interventional Pain Medicine*. This timely three-volume text significantly contributes to the field of minimally invasive spinal surgery and stands as an invaluable resource for current and future spine specialists, enhancing clinical practice and improving patient outcomes.

Eliete Bouskela
Presidente

Academia
Nacional de
Medicina



Sociedad Colombiana De Columna (SOCCOL)



The Sociedad Colombiana de Columna (SOCCOL) is a non-profit, autonomous, scientific organization dedicated to advancing spine care and surgery among orthopaedic and neurosurgeons, as well as other care professionals in Colombia. Founded to foster collaboration and innovation, SOCCOL brings together experts with diverse scientific interests and backgrounds. Our mission is to promote continuous professional development and education, ensuring our members stay at the forefront of the latest advancements in spinal care.

It is with great enthusiasm that I, on behalf of SOCCOL, endorse the three-volume book series *Neuroendoscopy & Interventional Pain Management*. This comprehensive text is particularly significant to SOCCOL due to its exemplary use of cutting-edge technology and detailed discussion of validated clinical endoscopic surgery protocols for the spine and neuroaxis.

The editors of this landmark series are distinguished leaders in minimally invasive spine surgery. Their collective expertise and dedication to advancing the field are evident throughout the volumes, making this series an invaluable resource for spine surgeons and affiliated professionals.

Dr. Kai-Uwe Lewandrowski, a pioneer in endoscopic spine surgery, has greatly contributed to the development and refinement of minimally invasive techniques. Drs. Jorge Ramírez, Alvaro Dowling, and William Contreras, esteemed members of the Latin American spine surgery community, have played key roles in promoting these advanced surgical practices across the region. Dr. Anthony Yeung and Dr. Xifeng Zhang, world-renowned experts, have extensively published on endoscopic spine surgery and interventional pain management, further solidifying the series' credibility. Drs. Morgan Lorio and Huilin Yang are visionary minimally invasive spine surgeons who have been instrumental in prompting policy changes at national and international levels.

Neuroendoscopy & Interventional Pain Management serves as a cornerstone for SOCCOL's continuing medical education programs. The comprehensive table of contents covers topics related to the cervical and lumbar spine, as well as advanced technological applications. This series will undoubtedly become an integral part of our educational initiatives, providing our members with the knowledge and tools necessary to excel in their practice.

I am honored to endorse this significant work on behalf of SOCCOL. The dedication and expertise of the editors have resulted in a reference text that will shape the future of spine surgery and enhance the quality of care for patients worldwide.

Dr. Connie Bedoya

President of SOCIEDAD COLOMBIANA DE COLUMNA (SOCCOL)

Sociedade Brasileira de Neurocirurgia (SBN)



The Brazilian Society of Neurosurgery (SBN), established in 1957 in Brussels and affiliated with the WFNS since 1959, has been instrumental in shaping neurosurgical education and practice in Brazil. Notably, SBN was one of the first societies in the country to require examinations for the title of master, beginning in 1972. SBN continues to encourage high standards in neurosurgery through continuous education and international collaboration and is deeply involved in shaping the curriculum and standards for neurosurgical residency programs, ensuring that both fundamental and clinical research are integral parts of neurosurgical training.

In line with our commitment to excellence, I am proud to endorse Neuroendoscopy & Interventional Pain Medicine on behalf of BSN. This textbook, crafted by global leaders in minimally invasive spine surgery, serves as an invaluable resource that will enhance the education and practice of future neurosurgical specialists.

Dr. Wuilker Knoner Campos

President,

Sociedade Brasileira de Neurocirurgia

Brazilian Society of Neurosurgery (SBN)

CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	iii
CHAPTER 1 THE IMPLICATIONS OF LOW BACK PAIN ON PROLONGED LIFESPAN AND FUTURE TARGETED CARE MODELS TO SUPPORT THE PURSUIT OF HEALTHY LONGEVITY	1
<i>fɪnktq'Fqy ɪkpi 'and' Mɛk'Wy g'Ngɪ cpftqy unk</i>	
INTRODUCTION	2
Commercialization	4
Aging	6
Degenerative Musculoskeletal Diseases	7
Precision Medicine	11
Targeted Care Models	12
CONCLUSION	13
REFERENCES	14
CHAPTER 2 CURRENT CONCEPTS AND LIMITS OF CELL-BASED REGENERATION STRATEGIES FOR DEGENERATIVE DISC DISEASE	16
<i>Cɪnktq'Fqy ɪkpi . 'O ct egrɪ 'O qɪkɛ . 'Y kɪkɔ 'Qo ct 'Eqpɪ gt cu'N»rg/ . 'O qti cp'R0 Nqtkɪ . 'Ughɛp'Nɛpfi tɛgdgt . 'Lɪti g'Hgrɪk g'Tco ʃg/ 'Ng»p'and' Mɛk'Wy g'Ngɪ cpftqy unk</i>	
INTRODUCTION	17
Normal Structures and Natural Healing	18
Normal Structure of the Intervertebral Disc	18
Pathophysiology	19
Mesenchymal Stem Cells	20
Adipose-Derived Stem Cells	21
The Difference between White and Brown Adipose Tissue	21
Harvesting	22
Stem Cell Formation and Identification	23
Mesenchymal Stem Cell Injection for DDD	24
Mechanism of Action of MSCs for DDD	25
MSC Clinical Trials	26
Functional versus Structural Improvements	27
The Ethics of MSC Therapies	27
CONCLUSION	27
REFERENCES	28
CHAPTER 3 CURRENT CLINICAL APPLICATIONS OF REGENERATIVE STRATEGIES FOR LUMBAR DEGENERATIVE DISC DISEASE AND GLOBAL DISEASE BURDEN DUE TO LOW BACK PAIN	34
<i>/fɪnktq'Fqy ɪkpi . 'O ct lɛp'Cuɪk 'Lɛko g'O q{cpq . 'Lɪti g'Hgrɪk g'Tco ʃg/ 'Ng»p . 'Mɛk'Wy g'Ngɪ cpftqy unk'ɛpf 'Y kɪkɔ 'Qo ct 'Eqpɪ gcu'N»rg/</i>	
INTRODUCTION	35
Global Disease Burden	36
Degenerative Disc Disease	40
The Molecular Basis of Disc Degeneration	41
Regenerative Strategies	42
Platelet-Rich Plasma (PRP)	43
Autologous Bone Marrow Mesenchymal Stem Cells	45

Current Evidence for Biologics in Clinical Management of Low Back Pain	46
CONCLUSION	47
REFERENCES	48
CHAPTER 4 CURRENT BIOENGINEERING STRATEGIES FOR INJURED OR DEGENERATIVE INTERVERTEBRAL DISCS	57
<i>Схэтq'Fqy rkpι 'anf'Octegrq'Oqrkpc</i>	
INTRODUCTION	57
Annulus Fibrosus Repair	60
Tissue Engineering for Annular Repair	64
Nucleus Augmentation and Injectables	65
Nucleus Replacement and Regeneration	66
Biomaterials	71
Annulus Fibrosus/nucleus Pulposus Bioengineering Strategies	72
DISCUSSION	75
CONCLUSION	76
REFERENCES	76
CHAPTER 5 CURRENT THERAPY STRATEGIES FOR VERTEBRAL ENDPLATES	83
<i>Схэтq'Fqy rkpι 'anf'Octegrq'Oqrkpc</i>	
INTRODUCTION	83
Physiology	84
Endplate and Skeletal Maturity	85
Vascularity	86
Neuroanatomy of the Vertebral Endplate	87
Endplate Failure Modes	88
Rationale for Endplate Treatment	90
Increasing Endplate Vascularity	91
Enhanced Biointegration	92
Clinical Studies	93
DISCUSSION	100
CONCLUSION	102
REFERENCES	102
CHAPTER 6 THE CURRENT CONCEPT FOR STEM CELL THERAPY IN SPINAL CORD INJURY	110
<i>Схэтq'Fqy rkpι 'anf'Octegrq'Oqrkpc</i>	
INTRODUCTION	110
Primary Injury	111
Secondary Injury	112
Chronic Phase and Neurodegeneration	112
American Spinal Cord Injury Association Scale	113
Determination of Neurological Level of Injury	114
ASIA Impairment Scale	114
Acute Injury Phase	119
History of Cell-based Therapy	121
Stem Cell Types	122
Bone Marrow-derived Mesenchymal Stem Cells	126
Umbilical Cord MSCs	126
Adipocyte MSCs	127
MSC Transplantation Strategies for Chronic SCI	127
MSC Benefit in Chronic SCI	129

Biomaterial Scaffolds and Hydrogels	131
Clinical Application	132
Addressing Ethical Concerns	134
DISCUSSION	135
CONCLUSION	136
REFERENCES	137
CHAPTER 7 ULTRASOUND-GUIDED AND SINGLE PORTAL ENDOSCOPIC CARPAL	
TUNNEL RELEASE	143
<i>O qti cp'RONqt kq'and'RewlRe vgt uqp</i>	
INTRODUCTION	143
Expectations	145
Indications	146
Contraindications	147
Special Considerations	148
Special Instructions, Position and Anesthesia	150
Tips and Pearls	151
SPECTR Tips	152
USCTR Tips	152
Difficulties	153
SPECTR Procedural Steps	154
SPECTR Bailout Procedure	156
USCTR Procedural Steps	156
USCTR Bailout Procedure	160
DISCUSSION	161
CONCLUSION	162
ACKNOWLEDGMENTS	162
REFERENCES	162
CHAPTER 8 OZONE AND PRP INJECTIONS FOR SYMPTOMATIC LUMBAR	
HERNIATED DISC	165
<i>Nwku'O li wgnF wej 2 p'Taf t f wgl.'Lati g'Hgrk g'Tco f gl'Ng»p.'Vcplk'Ct cpeklk</i>	
<i>/Dcur kpgkt q.'Ugrj cp'Mpqm'f nct q'F qy rki.'Y krik o'Qo ct'Eqvt gcu'N»r gl'and'Mck</i>	
<i>Wy g'Ngy cpf t qy un k</i>	
INTRODUCTION	166
Platelet Rich Plasma (PRP)	166
Ozone Therapy	167
MRI Changes after Intradiscal Ozone Injection	168
Clinical Indication for ozone-PRP disc therapy	169
Oxygen-Ozone Preparation and PRP Methodology	170
Preferred Autologous PRP Protocol	170
Injection Technique of Choice	170
Clinical Outcomes Following Ozone & PRP Treatment	171
DISCUSSION	172
CONCLUSION	174
REFERENCES	174
CHAPTER 9 ALLOGENEIC STEM CELL THERAPY FOR PAINFUL INTERMEDIATE	
LUMBAR DEGENERATIVE DISCS	181
<i>f nct q'F qy rki.'Lwcp'Ect nqu'Xgtc.'Lati g'Hgrk g'Tco f gl'Ng»p.'Y krik o'Qo ct</i>	
<i>Eqvt gcu'N»r gl.'O qti cp'RONqt kq'and'Mck'Wy g'Ngy cpf t qy un k'</i>	
INTRODUCTION	182

Allogeneic Mesenchymal Stem Cells (MSCs)	183
Allogeneic Stem Cell Disc Therapy: A Comprehensive Analysis	184
Mesenchymal Stem Cell Harvesting and Advanced Expansion Techniques	185
Intervertebral Disc Inoculation	186
Cohort-analysis	187
DISCUSSION	191
CONCLUSION	192
REFERENCES	192
SUBJECT INDEX	197

PREFACE

Welcome to Neuroendoscopy and Interventional Pain Medicine, Vol. 1: Regenerative Medicine & Peripheral Nerve Endoscopy, a comprehensive volume that explores the latest advancements in regenerative medicine and minimally invasive endoscopic techniques. This book brings together the expertise of leading practitioners and researchers at the forefront of these transformative fields.

The growing impact of low back pain on individuals' health and lifespan is a significant concern, and this volume begins by addressing this issue with a focus on future care models that support healthy longevity. The book offers insights into targeted strategies for improving patient outcomes. Advancements in cell-based regeneration are crucial for treating degenerative disc disease. The current concepts and limitations of these strategies, highlighting both the potential and challenges in this evolving field, are discussed in depth. The clinical applications of regenerative strategies are further explored by providing a global perspective on the burden of low back pain and the promise of innovative treatments. Bioengineering strategies for injured or degenerative intervertebral discs are examined, and cutting-edge approaches to disc repair and regeneration are presented. Additionally, an in-depth look at current therapy strategies for vertebral endplates is provided, summarizing valuable information on treatment options for these critical structures. Stem cell therapy holds great promise for spinal cord injury, and the current concepts and advancements in this area are discussed, showcasing the potential for significant breakthroughs in patient recovery and rehabilitation. Minimally invasive and endoscopic techniques continue to revolutionize peripheral nerve decompression, as in ultrasound-guided or single portal endoscopic carpal tunnel release. These innovative approaches offer less invasive solutions for patients suffering from carpal tunnel syndrome. The use of ozone and PRP injections for symptomatic lumbar herniated discs is covered, and the respective chapter provides insights into these emerging treatment modalities and their effectiveness in alleviating pain and improving function. Lastly, the potential of allogeneic stem cell therapy for painful intermediate lumbar degenerative discs is explored, offering a glimpse into the future of regenerative medicine for spinal conditions.

Each chapter in this volume is carefully selected to reflect contemporary trends and innovations in regenerative medicine and endoscopic techniques as they apply to neuroendoscopy and interventional pain management. This book aims to meet the demands of patients, healthcare providers, and policymakers by addressing the need for safer, more efficient, and cost-effective solutions. The editors hope that Vol. 1 of Neuroendoscopy and Interventional Pain Medicine: Regenerative Medicine & Peripheral Nerve Endoscopy serves as an invaluable resource for clinicians and researchers dedicated to advancing the field and improving patient care.

Kai-Uwe Lewandrowski

Center for Advanced Spine Care of Southern Arizona and Surgical
Institute of Tucson
Tucson, AZ, USA

William Omar Contreras López

Clínica Foscal Internacional
Autopista Floridablanca - Girón, Km 7, Floridablanca
Santander, Colombia

Jorge Felipe Ramírez León
Fundación Universitaria Sanitas
Bogotá, D.C., Colombia

Álvaro Dowling
Orthopaedic Spine Surgeon, Director of Endoscopic Spine Clinic
Santiago, Chile

Morgan P. Lorio
Advanced Orthopedics, 499 East Central Parkway
Altamonte Springs, FL 32701, USA

Assistant Editors

Hui-lin Yang
Professor & Chairman of Orthopedic Department
The First Affiliated Hospital of Soochow University
No. 899 Pinghai Road, Suzhou, China

Xifeng Zhang
Department of Orthopedics, Wangjing Hospital
China Academy of Chinese Medical Sciences, Beijing, China

&

Anthony T. Yeung
Desert Institute for Spine Care
Phoenix, AZ, USA

List of Contributors

- Álvaro Dowling** Orthopaedic Spine Surgeon, Director of Endoscopic Spine Clinic, Santiago, Chile,
- Jaime Moyano** Centro Regional Universitario BarilocheThe institution will open in a new tab, San Carlos de Bariloche, Argentina,
- Jorge Felipe Ramírez León** Minimally Invasive Spine Center. Bogotá, D.C., Colombia,
Reina Sofía Clinic. Bogotá, D.C., Colombia,
Fundación Universitaria Sanitas. Bogotá, D.C., Colombia,
- Juan Carlos Vera** Universidad de Chile, Santiago, Chile,
- Kai-Uwe Lewandrowski** Center for Advanced Spine Care of Southern Arizona and Surgical Institute of Tucson, Tucson, AZ, USA,
Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá, D.C., Colombia,
Department of Neurosurgery in the Video-Endoscopic Postgraduate Program at the Universidade Federal do Estado do Rio de Janeiro - UNIRIO, Rio de Janeiro, Brazil,
- Luis Miguel Duchén Rodríguez** Center for Neurological Diseases and Public University of El Alto, La Paz, Bolivia,
- Marcelo Molina** Orthopaedic Spine Surgeon, Clínica Las Condes, Instituto Traumatológico, Santiago, Chile,
Department of Orthopaedic Surgery, Faculdade de Medicina de Ribeirão Preto - USP (School of Medicine of Ribeirão Preto - University of São Paulo), Ribeirão Preto, SP, Brazil,
- Marjan Asefi** University of North Carolina, Greensboro, NC, USA,
- Morgan P. Lorio** Advanced Orthopedics, 499 East Central Parkway, Altamonte Springs, FL 32701, USA,
- Paul Paterson** Vero Orthopedics, 3955 Indian River Dr, Vero Beach, FL 32960, USA,
- Stefan Landgraeber** Universitätsdes Saarlandes, Klinik für Neurochirurgie, Kirrberger Straße 100, 66421 Homburg, Germany,
- Stephan Knoll** Biological Therapies Center, La Paz, Bolivia,
- Tania Arancibia Baspineiro** Center for Neurological Diseases, La Paz, Bolivia,
- William Omar Contreras López** Clínica Foscal Internacional, Autopista Floridablanca - Girón, Km 7, Floridablanca, Santander, Colombia,

CHAPTER 1

The Implications of Low Back Pain on Prolonged Lifespan and Future Targeted Care Models to Support the Pursuit of Healthy Longevity

Álvaro Dowling^{1,*} and Kai-Uwe Lewandrowski^{2,3,4}

¹ *Orthopaedic Spine Surgeon, Director of Endoscopic Spine Clinic, Santiago, Chile*

² *Center for Advanced Spine Care of Southern Arizona and Surgical Institute of Tucson, Tucson, AZ, USA*

³ *Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá, D.C., Colombia*

⁴ *Department of Neurosurgery in the Video-Endoscopic Postgraduate Program at the Universidade Federal do Estado do Rio de Janeiro - UNIRIO, Rio de Janeiro, Brazil*

Abstract: The human desire for everlasting youth and well-being has persisted throughout history. In the modern era, advancements in medicine and the emerging field of longevity have brought this age-old aspiration closer to realization. The remarkable increase in global life expectancy from a mere 30 years in 1870 to an impressive 71 years today, is a monumental healthcare achievement over the past century and a half. This achievement carries profound implications for the economy, necessitating a deeper understanding of the aging process and its influence on economic decision-making. Furthermore, it raises concerns regarding the adjustments required in behavior and lifestyle to adapt to extended lifespans while maintaining a high quality of life. The rise in life expectancy has substantial implications for managing chronic health conditions. Low back pain is nearly ubiquitous, and its global disease burden, particularly in high-socioeconomic standard countries, is high.

The youth and longevity business has carved out a niche from the traditional healthcare industry solely concerned with maintaining a high quality of life while managing the aging process. In this chapter, the authors deliver their perspective on the economic decision-making patterns of an aging population, the demographic changes associated with extended lifespans, and the adaptations in retirement planning and utilization of healthcare systems and social welfare programs. Further, the authors reflect on how aging spine patients adjust their behaviors and lifestyles to align with the demands of prolonged lifespans, prompting considerations of the economic consequences of these adjustments. The pursuit of healthy longevity raises questions about productivity, workforce participation, and the financial implications of supporting extended retire-

* **Corresponding author** Álvaro Dowling: Orthopaedic Spine Surgeon, Director of Endoscopic Spine Clinic, Santiago, Chile; E-mail: business@tucsonspine.com

ment periods. Healthy longevity refers to empowering individuals to lead longer lives while maintaining optimal physical, mental, and emotional well-being. Achieving healthy longevity entails making choices that significantly impact long-term health outcomes. The authors describe how the otherwise healthy low back pain patient over 50 should adopt a healthy lifestyle, including regular exercise, balanced nutrition, and stress management, to promote healthy aging while enhancing the quality of life during extended lifespans.

Keywords: Aging patients, Financial implications, Healthy longevity, Low back pain, Productivity, Workforce participation.

INTRODUCTION

For as long as human history has been documented, pursuing the fountain of youth has remained a steadfast endeavor driven by the desire to achieve an extended and healthier lifespan [1]. Today, fueled by remarkable advances in medical science and the exponential growth of the rejuvenation industry, this ancient dream is gradually becoming a reality. An astounding transformation in global life expectancy is a testament to the remarkable progress achieved over the past 150 years in healthcare. From a meager 30 years in 1870 (Fig. 1), the average lifespan has reached 71 years—an unprecedented milestone [2], leaving a significant health-to-life span gap of 9.2 years [3].




Fig. (1). Illustration of the health span to lifespan gap of 9.2 years [3].

Several considerations regarding longevity and low back pain are of concern [4]. Firstly, the substantial increase in life expectancy necessitates a deeper understanding of the aging process and its implications for economic decision-

making. With a population composed of individuals living longer, it becomes imperative to examine the complex dynamics of aging, low back pain, and its associated effects on various economic factors. Demographic shifts, such as an aging workforce and increased retirement periods, call for adaptations in retirement planning, social welfare systems, and healthcare services. Understanding the economic consequences of managing low back pain during a prolonged lifespan should enable patients, their physicians, policymakers, and economists to devise effective strategies that ensure economic stability and sustainability in the face of evolving demographic patterns [5].

Secondly, growing life expectancy raises pressing concerns about the necessary adjustments in behaviors and lifestyle habits to adapt to these long lifespans while preserving a high quality of life despite the burden of degenerative spine disease, which often manifests as low back and neurogenic claudication symptoms. From a practical point of view, it often means that patients need to reassess their choices and habits to navigate the challenges and opportunities presented by healthier longer lives. Associated factors affecting patients' life planning in their later years include financial and career management and healthcare utilization in the context of their overall well-being [1]. Such considerations are essential in enabling individuals to make informed decisions that optimize their well-being throughout their extended lifespans.

The ultimate goal of healthy longevity is to empower individuals to lead longer lives while maintaining optimal physical, mental, and emotional well-being. The key lies in making proactive and sustainable choices that positively impact long-term health outcomes. Engaging in a healthy lifestyle, encompassing regular exercise, a balanced diet, adequate sleep, stress management, and social connectedness, has been repeatedly shown to contribute to healthy aging and high quality of life significantly [1]. These lifestyle choices are fundamental pillars in the pursuit of healthy longevity, providing a robust foundation for individuals to age gracefully and enjoy enhanced well-being [6].

The authors of this chapter have become increasingly aware of a changing outlook in the healthy well-aging patient population and the need to offer treatments commensurate with the patient's goals and functional status. Low back pain is a significant concern for many of the authors' patients over age 50. These types of patients need to be better served by the spine care models running in public health care systems, where image-based criteria are often the foundation of medical necessity criteria for intervention or surgery. Frustrated, they often seek out the private practitioner for help. Hence, the need for a more structured care model for these highly functional patients - a care model that goes beyond the notion that healthy lifestyle choices profoundly impact long-term health outcomes and that

Current Concepts and Limits of Cell-Based Regeneration Strategies for Degenerative Disc Disease

Alvaro Dowling¹, Marcelo Molina², William Omar Contreras López^{3,*}, Morgan P. Lorio⁴, Stefan Landgraber⁵, Jorge Felipe Ramírez León^{6,7,8} and Kai-Uwe Lewandrowski^{9,10,11}

¹ Orthopaedic Spine Surgeon, Director of Endoscopic Spine Clinic, Santiago, Chile

² Orthopaedic Spine Surgeon, Clínica Las Condes, Instituto Traumatológico, Santiago, Chile

³ Clínica Foscal Internacional, Autopista Floridablanca - Girón, Km 7, Floridablanca, Santander, Colombia

⁴ Advanced Orthopedics, 499 East Central Parkway, Altamonte Springs, FL 32701, USA

⁵ Universitätsdes Saarlandes, Klinik für Neurochirurgie, Kirrberger Straße 100, 66421 Homburg, Germany

⁶ Minimally Invasive Spine Center. Bogotá, D.C., Colombia

⁷ Reina Sofía Clinic. Bogotá, D.C., Colombia

⁸ Fundación Universitaria Sanitas. Bogotá, D.C., Colombia

⁹ Center for Advanced Spine Care of Southern Arizona and Surgical Institute of Tucson, Tucson, AZ, USA

¹⁰ Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá, D.C., Colombia

¹¹ Department of Neurosurgery in the Video-Endoscopic Postgraduate Program at the Universidade Federal do Estado do Rio de Janeiro - UNIRIO, Rio de Janeiro, Brazil

Abstract: Degenerative disc disease stands as the predominant etiological factor behind low back pain. In recent years, the therapeutic modality of mesenchymal stem cell (MSC) infusion directly into the nucleus pulposus of the deteriorating disc has gained prominence. The intricacies of the intervertebral disc, a biomechanically robust tissue, span its components - the annulus fibrosus, nucleus pulposus, and cartilaginous endplates. Compromising the integrity of these elements can precipitate advanced disc degeneration due to biomechanical disruption. Animal models have demonstrated the therapeutic potential of MSCs. Particularly, adipose-derived stem cells (ASCs), a subset of MSCs originating from adipose tissue, possess attributes akin to their bone marrow-derived counterparts, metamorphosing into mesodermal structures, encompassing bone, cartilage, muscle, and fat. Their abundance in the human system,

* Corresponding author William Omar Contreras López: Clínica Foscal Internacional, Autopista Floridablanca - Girón, Km 7, Floridablanca, Santander, Colombia; Tel: +573112957003; E-mail: wylcon@gmail.com

coupled with minimally invasive extraction methods, makes them appealing for regenerative medicine applications. A comprehensive literature assessment presented in this chapter delineates the therapeutic paradigm of MSCs in addressing degenerative disc disease (DDD) pain. To date, research predominantly centered on the nucleus pulposus, while neglecting the annulus fibrosus and cartilaginous endplates. Notably, clinical manifestations like annular ruptures, Modic alterations, or Schmorl's nodal formations typically hint at pathologies within these overlooked structures. The prospects of successful regenerative interventions within the annulus, endplates, or nucleus pulposus remain controversial, considering the hostile, nutrient-deprived milieu of the deteriorating intervertebral disc often culminating in the swift demise of the introduced MSCs. Singularly targeting the compromised nucleus pulposus *via* existing MSC-centric regenerative modalities may not achieve disc restoration. Therefore, MSC-based therapeutic strategies should not just include the nucleus pulposus but also the affected annulus fibrosus and cartilaginous endplates.

Keywords: Intervertebral disc degeneration, Low back pain, Mesenchymal stem cells, Nucleus pulposus, Regenerative medicine.

INTRODUCTION

Low back pain, which plagues nearly 40% of the global populace, stands as a primary driver of musculoskeletal disability [1]. This affliction predominantly stems from degenerative disc disease (DDD), an insidious condition marked by the degradation of the extracellular matrix and the decline in cellular viability, especially within the nucleus pulposus [2]. As a potential countermeasure, the *In vivo* reintroduction of live cells into the nucleus pulposus, sourced either from the patient or external donors, is gaining traction as a viable avenue for disc regeneration [3]. The spectrum of cellular candidates under investigation for therapeutic interventions in disc degeneration includes notochordal cells, nucleus pulposus cells, annulus fibrosus cells, chondrocytes, mesenchymal stem cells (MSCs), embryonic stem cells, and induced pluripotent stem cells, among others [4 - 18]. Of particular interest are the MSCs, residing in assorted stem tissues. These cells encapsulate a diverse cohort comprising pluripotent stem cells, progenitors, and mature cells [20]. Their prolific origin, coupled with their innate potential for self-renewal and versatile differentiation, has elevated MSCs as a favored contender for revitalizing the intervertebral disc *via* transplantation. Contemporary clinical explorations have elucidated the utility of MSCs, either autonomously or synergistically with biomaterial frameworks, to rejuvenate compromised discs [2, 3]. While these strides are commendable, the MSC-therapies are not covered by most health insurance carriers.

Normal Structures and Natural Healing

The annulus fibrosus (AF) repair mechanism is hampered, in part, due to the scant cell populations' struggle to metabolize and renew extensive collagen fiber aggregations, an obstacle further exacerbated by a constricted vascular supply [19]. The sophisticated constitution of the AF poses considerable obstacles to tissue regeneration endeavors [20]. Contemporary knowledge offers a modest understanding of the AF's foundational cellular biology, notably concerning the origins and functional capacities of specific cell clusters, and their phenotypic transformations post-trauma or in disease states. The viability of regenerative modalities that can surmount the demanding mechanical stresses and austere intra-disc milieu to realize effective AF regeneration remains unanswered [21].

Architecturally, the AF is layered into 15-25 concentric laminae, with slanting collagen fibers organized parallelly within each lamina. These fibers' angle-ply orientation (θ) diminishes progressively from $\pm 62^\circ$ to $\pm 45^\circ$ relative to the vertical axis, transitioning from the disc's periphery towards its center [22]. Glycosaminoglycan proportions amplify from 3% to 8% per wet weight as one traverses from the AF's external to internal sectors, concurrent with a declining type I to type II collagen ratio. The inner AF predominantly hosts spherical fibrocartilaginous cells, while its exterior is rich in elongated fibroblast-resembling cells. The AF environment also nurtures diverse cell types, including peripheral, interlamellar, and stem/progenitor cells.

The cartilaginous endplate, a svelte hyaline cartilage layer, bears resemblances with articular cartilage. Despite comprehensive studies on articular cartilage restoration, the nuances of endplate repair remain comparatively less explored [22]. Past endeavors in cartilage regeneration often culminated in the emergence of fibrocartilage as opposed to reinstating the native collagen lattice, resulting in functional inadequacy. Consequently, the rejuvenation of pristine cartilaginous endplate structures becomes paramount in addressing back pain and preserving disc nutrient supply. However, the poorly understood mechanisms of endplate restoration, compounded by gaps in comprehension regarding its cellular biology and biomechanics, have stymied the formulation of efficacious therapeutic approaches targeting cartilaginous endplates in the context of low back pain.

Normal Structure of the Intervertebral Disc

The IVD is a fibrocartilage structure that connects the vertebral bodies, contributing to spine mobility and acting as a shock absorber. It consists of three main structures: the nucleus pulposus (NP), the annulus fibrosus (AF), and the cartilaginous endplates (CEPs). The NP, located at the core of the IVD, contains NP stem/progenitor cells, notochordal cells, chondrocyte-like cells, water, and

CHAPTER 3

Current Clinical Applications of Regenerative Strategies for Lumbar Degenerative Disc Disease and Global Disease Burden Due to Low Back Pain

Álvaro Dowling¹, Marjan Asefi², Jaime Moyano³, Jorge Felipe Ramírez León^{4,5,6}, Kai-Uwe Lewandrowski^{7,8,9} and William Omar Contreras López^{10,*}

¹ Orthopaedic Spine Surgeon, Director of Endoscopic Spine Clinic, Santiago, Chile

² University of North Carolina, Greensboro, NC, USA

³ Centro Regional Universitario Bariloche The institution will open in a new tab, San Carlos de Bariloche, Argentina

⁴ Minimally Invasive Spine Center. Bogotá, D.C., Colombia

⁵ Reina Sofía Clinic. Bogotá, D.C., Colombia

⁶ Fundación Universitaria Sanitas. Bogotá, D.C., Colombia

⁷ Center for Advanced Spine Care of Southern Arizona and Surgical Institute of Tucson, Tucson, AZ, USA

⁸ Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá, D.C., Colombia

⁹ Department of Neurosurgery in the Video-Endoscopic Postgraduate Program at the Universidade Federal do Estado do Rio de Janeiro - UNIRIO, Rio de Janeiro, Brazil

¹⁰ Clínica Foscal Internacional, Autopista Floridablanca - Girón, Km 7, Floridablanca, Santander, Colombia

Abstract: Degenerative disc disease, coupled with its consequential low back pain, presents a profound global health challenge, with efficacious clinical interventions still being subject to controversy. Cutting-edge strategies are being developed, targeting both pain mitigation and tissue regeneration. Both concentrated bone marrow aspirate and mesenchymal stem cells (MSCs) have displayed clinical potential in alleviating pain associated with degenerative disc disease. By harnessing molecular and genetic techniques, the utilization of growth factors, cytokines, and the modulation of autophagy and apoptosis processes offers hope in arresting disease progression, fostering tissue recuperation, and tempering inflammatory cascades. This chapter furnishes readers with a contemporary overview of therapeutic and regenerative modalities in clinical use and succinctly delineates the grading of the extant pinnacle clinical evidence.

* **Corresponding author William Omar Contreras López:** Clínica Foscal Internacional, Autopista Floridablanca - Girón, Km 7, Floridablanca, Santander, Colombia; Tel: +573112957003; E-mail: wyllecon@gmail.com

Kai-Uwe Lewandrowski & William Omar Contreras López (Eds.)
All rights reserved-© 2024 Bentham Science Publishers

Keywords: Autologous platelet-rich plasma, Autologous mesenchymal stem cells, Low back pain.

INTRODUCTION

Defined succinctly, low back pain is characterized by discomfort in the posterior region, spanning from the twelfth rib's lower margin to the lower gluteal folds, potentially extending into one or both lower extremities, persisting for a minimum of one day [1].

As global demographics trend older, the prevalence of low back pain intensifies, becoming a ubiquitous health concern. This ailment exerts considerable morbidity and places an economic strain on numerous healthcare systems internationally. Its genesis is multifaceted; while a fraction can be attributed to genetic predispositions [2], psychological etiologies are also implicated [3]. Traumatic events may exacerbate disc degeneration [4]. Predominantly, age-induced disc degeneration is identified as the primary precursor to debilitating low back pain, commonly initiated by intervertebral disc degeneration. Consequently, afflictions of the facet joints can result in restricted mobility, often accompanied by radiculopathy, or sciatica [5 - 7]. In extreme scenarios, the compression of the cauda equina can lead to nerve root damage, intense pain, paralysis, and urinary or fecal incontinence [8 - 10]. Predominantly, surgical interventions, either decompression alone or in combination with fusion, are the foremost treatments for discogenic low back pain arising from advanced degenerative disc disease [11 - 14]. Notably, artificial disc replacements [15, 16] and other innovative interventions [17 - 24] are frequently deemed unsuitable for advanced disease stages or have not met the rigorous criteria of the FDA's approval process.

Traditional surgical interventions, like laminectomy and fusion, frequently mandate hospital stays, especially among older adults [25, 26]. They may be fraught with complications: blood loss [27], dural tears [28], postoperative pain, infections [29, 30], and a myriad of other post-surgical challenges [25, 31 - 42] often necessitating unplanned post-operative care [43]. Additionally, these procedures carry a substantial risk of reoperation [44 - 46], commonly attributable to hardware malfunctions, degeneration escalation, spinal instability, or deformities [47 - 52]. The functional deterioration ensuing from such procedures underlines the imperative for alternative methodologies. The paradigm is gradually shifting towards early-stage, minimally invasive [53], and regenerative interventions [54 - 59], opposing the historical predilection for extensive late-stage surgical reconstructions.

Recent empirical evidence underscores the efficacy of minimal interventions, employing direct visualization for patients grappling with degenerative spinal

stenosis, potentially with concomitant disc herniation [43, 60 - 62]. Preservation of the intervertebral disc's innate shock-absorbing functionality in compromised spinal movement scenarios has been advocated and tested by several experts [63]. Given the limitations intrinsic to the conventional surgical approach for spinal ailments, burgeoning research is centered on pioneering interventional modalities. The expanding research corpus substantiates this trend [64]. This chapter endeavors to encapsulate the contemporary zenith in regenerative therapies for intervertebral disc degeneration, acknowledging that the scope might not be exhaustive, and myriad validated restorative methodologies might emerge in the future.

Global Disease Burden

Globally, degenerative spinal conditions are ubiquitously observed and are an escalating concern with advancing age. Such maladies exert profound strain on both individuals and the overarching healthcare infrastructure. Specifically, intervertebral disc degeneration stands out as a noteworthy contributor to this worldwide health challenge, often culminating in prolonged disabilities among the affected.

The esteemed Global Disease Burden (GBD) study characterizes low back pain as discomfort manifesting in the posterior torso, ranging from the twelfth rib's base to the lower gluteal contours, potentially radiating into the lower extremities, and persisting for at least a day. This ailment's global impact is profound: in 2019 alone, low back pain emerged as the predominant Level 3 contributor to years lived with disability (YLDs), accounting for an estimated 63.7 million (95% UI 45.0–85.2) YLDs or approximately 7.4% (6.2–8.7) of the global total (as illustrated in Fig. 1).

The GBD investigation encompassed a comprehensive assortment of studies on low back pain, including four centered on its incidence, 446 on prevalence, three on remission, and 15 others directly related to this ailment, with a conspicuous absence of studies focusing on its causes of death [65 - 68]. The 2019 iteration of the GBD study [67] diverged from its 2010 predecessor by omitting studies rooted in lifetime recall surveys, due to the variability in recall durations of lifelong back pain experiences exceeding the scope of a singular adjustment factor. Moreover, insurance data from Taiwan was disregarded due to its paucity. Corrections for potential biases were meticulously executed using meta-regression network analysis, specifically the Bayesian, regularized, trimmed approach (MR-BRT) [67, 69]. Adjustments accommodated studies that delineated overly extensive anatomical regions, episodes surpassing three months, varying recall periods, and constraints like pain that hampered activities. The analysis also accounted for

CHAPTER 4

Current Bioengineering Strategies for Injured or Degenerative Intervertebral Discs**Alvaro Dowling^{1,*} and Marcelo Molina²**¹ *Orthopaedic Spine Surgeon, Director of Endoscopic Spine Clinic, Santiago, Chile*² *Department of Orthopaedic Surgery, Faculdade de Medicina de Ribeirão Preto - USP (School of Medicine of Ribeirão Preto - University of São Paulo), Ribeirão Preto, SP, Brazil*

Abstract: The functionality of the intervertebral disc can be compromised due to aging and injuries. Synthetic and composite materials are investigated for disc repair to reduce pain. Synthetic materials or composite implants lack interaction with the disc's biological components and have yet to gain widespread usage or achieve desirable outcomes in treating intervertebral disc disorders. This chapter examines bioengineering approaches to disc repair, including cell-enhanced materials or biologically derived acellular materials that allow for cellular interactions and remodeling within the intervertebral disc. While still in its early stages, bioengineering techniques utilizing innovative biomaterials are showing promise as potential alternatives for the clinical treatment of intervertebral disc disorders.

Keywords: Annulus fibrosus, Disc degeneration, Degenerative disc disease, Fusion, Herniation, Intervertebral disc, Nucleus pulposus, Spine.

INTRODUCTION

The intervertebral disc (IVD) has historically been implicated in dorsalgia and has consequently undergone rigorous scientific scrutiny for the innovation of novel therapeutic modalities. The degenerative cascade within the IVD encompasses proteoglycan diminution, aberrations in extracellular matrix topography, annular fissures, formation of extruded discal fragments, and decrement in discal elevation [1 - 4]. Such morphological perturbations can culminate in radicular nerve encroachment, spinal canal stenosis, and facet joint infringement, thereby manifesting as nociceptive experiences and neurological insufficiencies [5, 6]. Additionally, the inflammatory microenvironment and neoinnervation observed within compromised discs have been postulated as etiological agents of discogenic dorsalgia [7]. Consequently, the multifaceted genesis of discogenic

* **Corresponding author: Álvaro Dowling:** Orthopaedic Spine Surgeon, Director of Endoscopic Spine Clinic, Santiago, Chile; E-mail: adowling@dws.cl

back pain involves intricate interplay amongst biomechanical attributes of the IVD, systemic inflammation, and neurophysiological systems (both peripheral and central) [8].

In light of their prospective efficacy in symptom alleviation and functional restitution, tissue engineering and regenerative medicine approaches have elicited considerable scholarly attention as pre-surgical interventions aimed at decelerating or even reversing the ongoing trajectory of IVD degradation and its concomitant nociceptive and dysfunctional symptomatology. These paradigms possess the unique merit of concurrently targeting the biomechanical, immunological, and neurophysiological dimensions implicated in IVD pathophysiology.

Contrary to the prevailing perception that the intervertebral disc (IVD) possesses a restricted regenerative aptitude following trauma (as illustrated in Fig. 1), emergent insights into IVD ontogenesis, cellular biology, and mechanisms of degeneration portend the feasibility of cellularly-mediated rejuvenation [4]. Research has elucidated that the intrinsic cellular constituencies of the IVD exhibit a responsiveness to biomechanical provocations, such as substrate rigidity, and to an array of chemotactic and pro-inflammatory molecules, including but not limited to, chemokines and cytokines that modulate metabolic pathways and extracellular matrix assembly [9, 10]. Furthermore, aging-associated infiltration of macrophages and monocytes within the IVD has been demonstrated to modulate disc cell phenotypic expression, biosynthetic activity, and longevity. Bioengineering modalities represent a propitious avenue for directing cellular assimilation into implantable materials, representing a notable enhancement over erstwhile “inert” prosthetic devices that culminated in suboptimal clinical outcomes. There exists an escalating academic focus geared toward the refinement of both biological and bioengineering methodologies that capitalize on the endogenous cellular components resident within the IVD.

In this chapter, the authors proffer a succinct survey of clinical investigations that employ biomaterials as vectors for either cellular or pharmacological delivery. These investigations elucidate approaches for either the complete or partial restitution of the intervertebral disc (IVD) using cellularly-augmented as well as acellular, biologically-derived substrates that facilitate cellular-material interaction and architectural reorganization. Various preclinical and clinical inquiries have scrutinized the ramifications of infusing both allogeneic and autologous progenitor and stem cell lineages into the IVD milieu [11, 12]. Although the objectives aligned with cellular or drug deployment may intersect those of engineered biomaterials, such as restoring discal elevation, mitigating neural encroachments, or reversing radiological manifestations of pathology, the

complex landscape of regulatory approval coupled with the intense requirement for precise cellular introduction into the IVD has engendered work that transcends a consensus-oriented conceptualization of best practices.




Fig. (1). In a healthy disc (left panel), the annulus fibrosus (outer layer) and nucleus pulposus (inner gel-like core) maintain their structural integrity and provide cushioning, flexibility, and shock absorption. In a degenerative lumbar intervertebral disc (right panel), the annulus fibrosus develops fissures leading to disc bulging or herniation. The nucleus pulposus may lose hydration and elasticity, becoming less capable of absorbing mechanical stresses resulting in reduced disc height and impaired disc function. Degenerative discs often are associated with osteophytes, spinal instability, nerve compression, and chronic low back pain.

In this context, the authors will delineate evolving methodologies and innovative breakthroughs involving biomaterials that are either in contemporary utilization or

CHAPTER 5

Current Therapy Strategies for Vertebral Endplates

Alvaro Dowling^{1,*} and Marcelo Molina²

¹ Orthopaedic Spine Surgeon, Director of Endoscopic Spine Clinic, Santiago, Chile

² Department of Orthopaedic Surgery, Faculdade de Medicina de Ribeirão Preto - USP (School of Medicine of Ribeirão Preto - University of São Paulo), Ribeirão Preto, SP, Brazil

Abstract: The vertebral endplate is a critical component of the intervertebral disc, and its dysfunction can lead to various spinal disorders and chronic back pain. The structure and function of the vertebral endplate play an important role in disc nutrition, biomechanical support, and waste removal. Endplate-related conditions and their respective pathophysiologies may play a role in painful degeneration, fractures, and Modic changes. This chapter summarizes current concepts of therapeutic strategies with an emphasis on regenerative medicine application. It discusses using mesenchymal stem cells, platelet-rich plasma, growth factors, and tissue engineering approaches for endplate regeneration and repair. Diagnostic strategies for assessing vertebral endplate disorders and palliative as well as regenerative treatment strategies are discussed. The current evidence, ongoing research, and prospects in endplate-based therapies are highlighted.

Keywords: Annulus fibrosus, Disc degeneration, Degenerative disc disease, Fusion, Herniation, Intervertebral disc, Nucleus pulposus, Spine.

INTRODUCTION

Insufficient nutrient influx coupled with catabolic waste accrual are salient factors in the pathogenesis of intervertebral disc degeneration [1-6]. Given the disc's avascular constitution, it predominantly relies on vertebral endplates as essential conduits for nutrient facilitation [7, 8]. This solute transfer is orchestrated *via* an intricate network involving capillary beds and vascular interconnections between the osseous marrow recesses and the hyaline cartilaginous structure of the endplates [6, 9-12]. These vascular interfaces are imperative for cellular metabolic functions and the biofabrication of extracellular matrix components. Moreover, the effective expulsion of metabolic byproducts, notably lactic acid, is quintes-

* **Corresponding author:** Álvaro Dowling: Orthopaedic Spine Surgeon, Director of Endoscopic Spine Clinic, Santiago, Chile; E-mail: adowling@dws.cl

sential for averting their intradiscal accumulation [13]. Further, osmotic regulation *via* endplate-mediated water diffusion maintains intradiscal pressure equilibrium, which in turn contributes to disc height and mechanical functionality [14, 15].

Substantial empirical substantiation posits a robust correlative link between disc degenerative phenomena and concomitant alterations in adjoining endplates. Studies, exemplified by those conducted by Nachemson *et al.*, unveil a significant association between reduced endplate permeability and degenerative disc maladies [16]. Histological annotations indicate that disc degeneration is often presaged by lesions and microfractures within the endplates [17-19]. Additionally, age-associated calcification of endplate cartilage and the ensuing occlusion of nutrient conduits have been empirically observed. Radiological diagnostics, encapsulated by variations in MRI signal intensities in the vertebral marrow and morphological endplate alterations, manifest a strong linkage to degenerative disc conditions [22, 23]. Further, the aperture density within endplates has been ascertained to have a significant correlation with the degree of observed morphological deterioration [24].

Common interventional paradigms for mitigating disc degeneration encompass discectomy followed by scaffold implantation within the intradiscal environment. However, the efficacious implementation of these regenerative scaffolds is inexorably contingent upon the structural and functional integrity of the endplates. In instances where endplates exhibit sclerotic or hypertrophic characteristics, the anticipated restorative efficacy of the scaffold becomes critically compromised, owing predominantly to impeded fluidic and nutrient permeation. Thus, a compromised foundational architecture in the form of defective endplates ultimately undermines the holistic objectives oriented towards disc remediation.

Physiology

Endplates are composite structures characterized by both osseous and hyaline cartilaginous elements, discernible from embryonic developmental phases [25]. The osseous segment undergoes co-ossification with adjoining vertebral entities, while the cartilaginous component persists throughout standard ontogeny, eliciting noteworthy scientific attention. This cartilage portion is constituted by a hydrogel-like matrix replete with proteoglycan macromolecules, buttressed by a reticulum of collagen fibrils. Contrary to articular cartilage in diarthrodial joints, these collagenous fibrils refrain from direct osseous anchoring to the vertebral corpus [26]. Nevertheless, the endplate retains its proximal interface with the intervertebral disc *via* the inner annulus fibrosus lamellae [27]. During axial skeletal maturation, capillary networks transiently invade the endplates, furnishing requisite nutrients to the disc [25]. These vasculatures regress upon the

attainment of skeletal maturity, rendering mature discs largely dependent on solute diffusion across the endplates for sustenance and metabolic reciprocity [28].

Expansive scientific exploration has interrogated the endplate's biochemical constitution under physiological homeostasis and diverse degenerative paradigms [29, 30]. Of the various collagen subtypes identified within the disc, Type X collagen accrues particular significance in endplate pathophysiology, serving as a surrogate marker for hypertrophic chondrocytes and participating in calcification cascades [31]. Intriguingly, targeted abrogation of one Collagen II gene allele in murine models precipitates diminished glycosaminoglycan content within endplates, engendering abnormally thickened and precociously calcified structures [32]. These proteoglycan moieties play pivotal roles in modulating osmotic dynamics and maintaining hydric equilibrium within endplate cartilaginous matrices [33]. Their diminution correlates with concomitant proteoglycan deficits within the nucleus pulposus, implicating proteoglycan attrition as a likely precursor to disc degenerative processes [34].

Additional biochemical alterations in the endplates during skeletogenesis may impart a contributory role in the etiopathogenesis of conditions like scoliosis [35-37]. Comprehensive metabolic and nutritional studies of the disc have employed diverse *In vitro* models, substantiating the endplate's cardinal role in metabolic orchestration [16]. Notably, lateral peripheries of the endplate adjacent to vertebral rims exhibit reduced permeability *vis-a-vis* its central or annular counterparts [9, 28]. Morphometric analyses employing post-mortem human specimens have revealed a differential distribution of microvascular networks, with central endplate regions possessing augmented capillary densities relative to peripheral disc areas [3, 38]. This circulatory infrastructure, visualized through specialized injection techniques, corroborates that primary nutrient influx into the disc is mediated by diffusional transfer of minute solutes from these microvessels [7, 39]. However, this permeability is selective, governed by molecular dimensions and ionic polarity. The nucleus pulposus' high proteoglycan content endows it with a net negative electrostatic charge, thereby facilitating the ingress of cations like sodium and calcium, in addition to neutral entities like glucose and oxygen, whilst obstructing the transit of anions such as sulfate and chloride, as well as larger macromolecules like immunoglobulins and enzymatic compounds.

Endplate and Skeletal Maturity

Upon the attainment of skeletal maturity, the cartilaginous architecture of the endplate undergoes pronounced metamorphosis, culminating in substantive mineralization—a process subsequently reversed through osteoclastic resorption and osseous substitution [20, 40]. This emergent tissue composition impinges

The Current Concept for Stem Cell Therapy in Spinal Cord Injury

Alvaro Dowling^{1,*} and Marcelo Molina²

¹ Orthopaedic Spine Surgeon, Director of Endoscopic Spine Clinic, Santiago, Chile

² Department of Orthopaedic Surgery, Faculdade de Medicina de Ribeirão Preto - USP (School of Medicine of Ribeirão Preto - University of São Paulo), Ribeirão Preto, SP, Brazil

Abstract: Spinal cord injury with neurological deficits is devastating to patients and their families. After the immediate treatment that may involve spinal decompression and stabilization surgeries, patients are typically left with long-term disability. Intense research has focused on spinal cord regeneration, tissue repair, and reinnervation to improve function. Stem cell-based therapies are at the center of this effort. This chapter summarizes common spinal cord injury (SCI) patterns, including complete and incomplete SCIs, and their classification-based prognosis and treatments. They review the types of stem cells used in preclinical and clinical trials in the treatment of SCI and the associated ethical concerns and summarize the current state of the art of stem cell-based SCI treatments.

Keywords: Classification, Prognosis, Spinal cord injury, Stem cells, Treatment.

INTRODUCTION

Spinal cord injuries (SCIs) represent a formidable public health problem, manifesting an incidence range of 40 to 80 cases per million individuals annually, according to existing epidemiological data [1]. Predominantly afflicting a younger demographic, these injuries occasion irremediable neurological deficits that exert an onerous toll on patients, healthcare providers, and medical infrastructures alike. While prophylactic measures targeting vehicular mishaps, unlawful conduct, and secondary etiological factors such as neoplastic or degenerative pathologies are indisputably vital, the true challenge confronting the scientific community lies in the domain of therapeutic intervention, especially in the absence of a universally recognized, efficacious treatment modality.

* Corresponding author **Álvaro Dowling:** Orthopaedic Spine Surgeon, Director of Endoscopic Spine Clinic, Santiago, Chile; E-mail: adowling@dws.cl

Recent years have witnessed salient advancements in specialized, multidisciplinary methodologies for addressing SCI. Noteworthy among emerging organizational entities committed to this specialized sector of neurological injury is the International Association of Neurorestoratology (IANR). Such professional assemblies underscore the efforts to surmount a yet unresolved clinical impasse.

Within the scope of contemporary neurological practice, the re-establishment of functional capabilities post-SCI remains a daunting enterprise. This necessitates the employment of a spectrum of neurorestorative tactics throughout the acute, subacute, and chronic temporal stages of SCI, aimed at the reversing functional losses.

Primary Injury

The spinal cord of mammals is organized into ten laminae of neurons, named dorsoventrally, according to the Rexed description [2]. The neurons are mostly multipolar and vary in size. In the dorsal laminae, sensory neurons receive inputs from the dorsal root ganglion cells and project them to other spinal levels or the upper centers of the sensory pathways.

Within the dorsal laminae, sensory neurons act as afferent conduits for dorsal root ganglion cells, directing somatosensory information to alternate spinal echelons or more rostral sensorimotor processing centers. Conversely, the ventral laminae house substantial populations of cholinergic motor neurons, which orchestrate myogenic contractions *via* efferent axonal pathways. An intermediary locus is occupied by morphologically diverse interneurons, recipients of both descending corticospinal projections and recurrent axonal fibers from spinal motoneurons, thereby modulating motoneuronal discharge patterns [3, 4]. Neuronal constituents within the spinal cord forge intricate intraspinal circuitries under the governance of descending neural pathways, with the reflex arc representing the most rudimentary of such closed-loop systems.

During the acute temporal phase of SCI, the underlying traumatic etiology may encompass a variety of mechanical insults, such as contusions, lacerations, tensile forces, compressional impacts, or outright cellular obliteration. These initial traumatic events culminate in the primary injury phase, characterized by disintegration of neural circuitries [5]. In the immediate post-injury interval, typically within the first two hours [6], cellular constituents, including both neurons and glial entities at the lesion nexus, succumb to either necrotic or apoptotic fates [7]. Ergo, therapeutic objectives in post-SCI management should prioritize the restitution of native intraspinal circuitry, followed by the facilitation of regenerative growth in descending pathways, to re-establish volitional governance over these circuits. It is unequivocally acknowledged that the most

pivotal juncture in the pathophysiological trajectory of SCI pertains to the secondary injury phase. This latter phase is typified by an unchecked, maladaptive cascade involving aberrant molecular signaling pathways, inflammatory cascades, vascular aberrations, and consequent cellular dysregulations, further exacerbating the initial insult [8-11].

Secondary Injury

Within the context of an injured spinal cord, a spectrum of destructive mechanisms disturbs the local microenvironment, the severity of which is contingent upon the characteristics of the primary injury. In terms of vascular pathology, there occurs a widespread attenuation of blood perfusion attributable to phenomena such as vasospasms, focal microhemorrhagic events, and thrombotic incidents, collectively leading to a comprehensive compromise of the blood-spinal cord barrier integrity [8, 12]. Concurrently, a dysregulation in ionic equilibrium manifests around cellular membranes and associated ion transport machinery. Specifically, an efflux of potassium ions (K^+) is observed in the extracellular milieu, concomitant with an intracellular accrual of sodium (Na^+) and calcium ions (Ca^{2+}) [8, 13]. These perturbations result in the attenuation of neuronal signal transduction capabilities.

An acidotic milieu further exacerbates this dysfunctional state by facilitating the ingress of water molecules into the cellular compartment, culminating in cytotoxic edema and subsequent cellular demise [14-16]. The injurious cascade also precipitates the release of multiple biochemical entities, including reactive oxygen species and various neurotransmitters. Immunologically, the breach in the blood-brain barrier inaugurates the recruitment and infiltration of immune cells—such as T lymphocytes, macrophages, microglia, and neutrophils—into the neuronal matrix, thereby adopting a proinflammatory phenotype. The ensuing milieu is further enriched by the secretion of a cadre of proinflammatory cytokines, including but not limited to, Interleukin-1 beta ($IL-1\beta$), Interleukin-1 alpha ($IL-1\alpha$), Tumor Necrosis Factor-alpha ($TNF-\alpha$), and Interleukin-6 ($IL-6$). These factors collectively contribute to a localized cellular assembly that fosters neurodegenerative processes [17-19].

Chronic Phase and Neurodegeneration

In the chronic phase of spinal cord injury (SCI), a hallmark feature is the fibrotic encapsulation engendered by gliotic processes and the accretion of extracellular matrix components, thereby attenuating functional capacity. Bioactive molecules harboring anti-proliferative properties are liberated, targeting specific neuronal receptor complexes. The demise of oligodendrocytes during the primary injury event is of particular importance, given that the resulting myelin detritus harbors

CHAPTER 7

Ultrasound-Guided and Single Portal Endoscopic Carpal Tunnel Release

Morgan P. Lorio^{1,*} and Paul Paterson²

¹ *Advanced Orthopedics, 499 East Central Parkway, Altamonte Springs, FL 32701, USA*

² *Vero Orthopedics, 3955 Indian River Dr, Vero Beach, FL 32960, USA*

Abstract: As surgeons evolve to minimize morbidity and maximize outcomes or return-to-work (RTW) in the treatment of carpal tunnel syndrome (CTS), so have both single portal neuro-endoscopy and ultrasound-guided (US) technical applications procedurally in the safe, effective, and complete release/transection of the transverse carpal ligament (TCL). The chapter is intended as an independent complete go-to content-repository for surgeons desiring to revisit/review a relevant topic or area of thought without needing to reread the entirety of the same prior to a surgical case as a quick refresher. For those surgeons who have either mastered neuro-endoscopy or remain a novice, US techniques may offer patients new possibilities through the simple overlay of novel instruments and instructions over one's accumulated past experience.

Keywords: Carpal tunnel syndrome, Carpal tunnel release, Endoscopy, Ultrasound.

INTRODUCTION

Learmonth described the first open surgical release of the TCL in 1933 [1]. Brain and Phalen, respectively, defined idiopathic CTS from both clinical and anatomopathological points of view [2, 3]. SPECTR (Single Portal Endoscopic Carpal Tunnel Release) and USCTR (Ultrasound Guided Carpal Tunnel Release) are two modern surgical techniques that have emerged as advancements in the treatment of CTS. While they share the common goal of alleviating pressure on the median nerve, their historical origins and overlap in development have distinctive characteristics. Open procedures utilize extensile exposure to protect vital structures during surgery. However, open-approach techniques create surgical morbidity in normal tissues. Over time, surgeons have sought to minimize morbidity, leveraging technological advances to create minimally inva-

* **Corresponding author Morgan P. Lorio:** Advanced Orthopedics, 499 East Central Parkway, Altamonte Springs, FL 32701, USA; E-mail: mloriomd@gmail.com

sive solutions without sacrificing safety or efficacy. The result has been to reduce patient recovery times and complications inherent in open techniques. The origins of SPECTR can be traced back to the introduction of endoscopic techniques in the late 1980s. Until recently, surgeons have been traditionally divided into three main camps: standard open/extensile (34%), mini-open (46%), and endoscopic (20%) (See Fig. 1) [4]. In 1989, Chow *et al.* technically reported a dual-portal endoscopic carpal tunnel release (ECTR) [5]. After that, in 1992, Agee *et al.* detailed his SPECTR technique in a prospective randomized control trial (PRCT) using a transverse incision in the area of the proximal wrist crease [6]. This pistol-shaped 3M® Agee device evolution led to the birth of SPECTR, with the primary objective of providing enhanced visualization and reduced tissue trauma. MicroAire® Surgical Instruments later purchased the 3M® Agee device. A subsequent PRCT in 2002 by Trumble and Diao *et al.* demonstrated an equally safe and faster recovery (faster RTW) with SPECTR compared to open release [7]. Both co-authors of this book chapter were blessed to have been orthopedic residents in training within SUNY-Buffalo, a Beta-site for Agee’s Hand Biomechanics Lab; both have 30 years of experience with SPECTR. The development of specialized instrumentation and improved surgical techniques have contributed to the refinement of SPECTR over the years with a proliferation of devices, including the Arthrex® Centerline ECTR, which shares a very similar ergonomic profile with USCTR paralleling the longitudinal axis of the forearm and wrist while using direct neuro-endoscopic visualization in the former and ultrasound visualization in the latter. In 2010, Arthrex® settled a patent infringement spat with MicroAire®, and now MicroAire® licenses its patented ECTR technology to Arthrex® with both companies agreeing to “maintain Microaire’s practice of requiring surgeon training for the procedure” [8].




Fig. (1). Treatment of CTS (adapted from a 2012 survey of the American Association of Hand Surgery).

Although SPECTR and USCTR have distinct historical origins, there is an overlap in their evolution and technological advancements. Both techniques aim to minimize invasiveness and improve outcomes in the surgical treatment of CTS. They demonstrate the ongoing efforts within the surgical community to refine and optimize procedures to benefit patients. The development of specialized instrumentation, improved imaging modalities, and the integration of minimally invasive principles have contributed to the evolution and overlap of SPECTR and USCTR as valuable personalized precision treatment options for CTS. This chapter will attempt to describe both techniques simultaneously to avoid redundancy and expound where it is necessary to differentiate the distinctly different characteristics and nuances of each when appropriate.

Expectations

Two prominent techniques have gained recognition in the realm of minimally invasive surgical options for CTS: SPECTR and USCTR. With the increasing demand for less invasive approaches, patients and surgeons alike are eager to understand the expectations associated with the procedures. SPECTR offers the advantage of enhanced direct and familiar visualization with precise surgical intervention within the carpal tunnel, leading to potentially improved outcomes with Level I Evidence [9]. On the other hand, USCTR provides a guided and controlled release of the TCL, with minimal incision and potential for faster recovery. This chapter explores the innovations associated with these innovative techniques, highlighting their respective benefits, limitations, and anticipated outcomes, ultimately aiding clinicians and patients in making informed decisions regarding the optimal approach for CTR.

The anatomic expectation of either procedure is a complete release of the TCL, thereby releasing compression on the carpal tunnel contents, specifically the median nerve. In 1994, using advanced MRI techniques, Ablove *et al.* at SUNY-Buffalo validated that both SPECTR and a dual-portal subcutaneous CTR morphologically produced a marked increase in canal volume and median nerve cross-sectional area, suggesting equivalence to open release [10]. After that, in 1996, Ablove *et al.* found that pressures decreased in both the carpal tunnel and Guyon's canal (GC) after both endoscopic and open release, suggesting that CTR alone may be sufficient to relieve symptomatic carpal and ulnar tunnel syndromes [11]. Recently, Peters *et al.*, in 2021, using an MRI protocol, confirmed no significant morphologic differences between Agee SPECTR and open release, with both resulting in a significant increase in the AP dimensions of the carpal tunnel and GC, respectively [12]. Likewise, Occam's razor or the 'law of parsimony' would suggest that a successful USCTR would have similar results.

CHAPTER 8

Ozone and PRP Injections for Symptomatic Lumbar Herniated Disc

Luis Miguel Duchén Rodríguez¹, Jorge Felipe Ramírez León^{2,3,4}, Tania Arancibia Baspineiro⁵, Stephan Knoll⁶, Álvaro Dowling⁷, William Omar Contreras López⁸ and Kai-Uwe Lewandrowski^{9,10,11,*}

¹ Center for Neurological Diseases and Public University of El Alto, La Paz, Bolivia

² Minimally Invasive Spine Center. Bogotá, D.C., Colombia

³ Reina Sofía Clinic. Bogotá, D.C., Colombia

⁴ Fundación Universitaria Sanitas. Bogotá, D.C., Colombia

⁵ Center for Neurological Diseases, La Paz, Bolivia

⁶ Biological Therapies Center, La Paz, Bolivia

⁷ Department of Orthopaedic Surgery, USP, Ribeirão Preto, Brazil

⁸ Clínica Foscal Internacional, Autopista Floridablanca - Girón, Km 7, Floridablanca, Santander, Colombia

⁹ Center for Advanced Spine Care of Southern Arizona and Surgical Institute of Tucson, Tucson, AZ, USA

¹⁰ Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá, D.C., Colombia

¹¹ Department of Neurosurgery in the Video-Endoscopic Postgraduate Program at the Universidade Federal do Estado do Rio de Janeiro - UNIRIO, Rio de Janeiro, Brazil

Abstract: Low back pain from arthritic lumbar facet joints and painful degenerative lumbar discs is widespread and one of the world's most disabling diseases, consuming significant health care resources. In this chapter, the authors report using autologous platelet-rich plasma (PRP) and ozone spinal injections into arthritic lumbar facet joints and painful lumbar degenerative discs to treat inflammatory pain. A prospective observational cohort study from January 2016 to March 2020 was performed at an outpatient clinic of a single academic medical center to assess these injections' safety and therapeutic effectiveness in conjunction with epidural transforaminal epidural steroid injections. Results indicated functional improvements measured by Oswestry Disability Index (ODI) and modified MacNab criteria and pain measured by visual analog scale leg pain (VAS) at rest and during flexion. Although our study was limited in scope, and by the observational nature of our research and the lack of randomized

* **Corresponding author Kai-Uwe Lewandrowski:** Center for Advanced Spine Care of Southern Arizona and Surgical Institute of Tucson, Tucson, AZ, USA; Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá, D.C., Colombia and Department of Neurosurgery in the Video-Endoscopic Postgraduate Program at the Universidade Federal do Estado do Rio de Janeiro - UNIRIO, Rio de Janeiro, Brazil; E-mail: miguelduchen@hotmail.com

and double-blinding, our work suggests that rapid pain reduction and functional gains may materialize in patients with low back pain due to herniated disc after spinal injections with ozone and activated PRP.

Keywords: Low back pain, Ozone, Autologous platelet-rich plasma, Spinal injection.

INTRODUCTION

Chronic lumbar pain predominantly arises from intervertebral disc degeneration. In contrast, acute episodes of severe pain in the lower back and leg, resembling sciatica, usually result from herniated lumbar discs, adversely impacting patients' daily life and productivity. Such conditions pose a significant medical challenge. Lumbar degenerative disc disease has emerged as a pressing global concern, particularly prevalent among the aging population [1, 2]. Current treatments encompass conservative methods: anti-inflammatory medication, physical therapy, and microdiscectomy. Yet, the surgical route might expedite degeneration, potentially demanding further interventions [3 - 7].

In the 1980s, chymopapain, a cysteine protease from papaya latex, was a popular choice for chemical nucleolysis in patients with persistent herniated disc symptoms. Due to complications, its use was discontinued [8]. In the same decade, intradiscal oxygen/ozone injections for symptomatic lumbar herniations were introduced [9]. Numerous studies [9 - 22] and select randomized trials [12, 13, 23 - 26] have since underscored the efficacy of ozone therapy, either standalone or combined with steroids and other inflammation-reducing agents. Techniques, such as periradicular and intraforaminal injections, have proven beneficial in managing lumbar herniated disc pain [21, 23, 25, 27 - 32].

Ozone's primary *modus operandi* is believed to be chemonucleolysis, as it interacts with proteoglycan GAGs that help retain intradiscal osmotic balance, causing them to decompose. This leads to the nucleus pulposus dehydrating, thereby reducing disc volume. Moreover, ozone's inherent antimicrobial properties negate the need for preventive antibiotics [33]. Interactions with intradiscal cytokines may further produce an anti-inflammatory effect, diminishing pain levels, as supported by animal studies [34, 35]. Imaging analyses, including CT and MRI scans, have confirmed the reduced size of ozone-treated herniated lumbar discs [26, 36 - 39].

Platelet Rich Plasma (PRP)

Platelet Rich Plasma (PRP), derived from autologous sources, has shown promise in alleviating pain associated with symptomatic lumbar herniated and

degenerative black discs [40]. PRP is essentially a concentrated blend of platelets suspended in a minimal volume of plasma. Its therapeutic potential arises from its capacity to promote extracellular matrix synthesis, which in turn may catalyze wound repair and intradiscal regeneration [41]. On a molecular front, PRP appears to modulate cytokine secretion, promoting the release of anti-inflammatory agents while suppressing pro-inflammatory cytokines. This modulation doesn't trigger immune reactions due to the autologous origin of the PRP [42].

Mirroring ozone's properties, PRP possesses anti-inflammatory and anti-microbial characteristics, thus potentially minimizing infection risks post-spinal injections [4, 5]. Several in vitro studies have confirmed the multifaceted advantages of PRP on degenerative disc tissues [6]. Notably, PRP has been associated with the rejuvenation of denatured discs by enhancing glycosaminoglycan concentrations [43]. Contemporary clinical findings indicate PRP's efficacy in pain mitigation related to lumbar disc conditions. However, concrete evidence verifying structural and functional enhancements remains elusive [44].

In the referenced prospective observational cohort study, the authors delve into the synergistic effects of ozone combined with activated PRP, aiming to optimize therapeutic outcomes for patients suffering from painful lumbar herniated discs.

Ozone Therapy

Ozone [$O_{(2)}$, $O_{(3)}$] has been applied in the treatment of herniated discs. It also is believed to have therapeutic effects. Chemically, ozone is a highly reactive form of oxygen. It has been employed in the treatment of painful lumbar disc herniations. In addition to anti-inflammatory effects, it has been proposed to have analgesic properties [22]. The latter property was attributed to alleviating pain stemming from acute lumbar disc herniations by modulating the pain signaling pathways, reducing inflammation, and inhibiting the release of pain-inducing substances in the affected area. Ozone therapy may promote also cause shrinkage or dissolution of the herniated disc material by inducing oxidation. The resulting breakdown of diseased disc material [16, 17, 24] has been instrumental in patients with sciatica-type back and leg symptoms from extruded herniated discs. The resultant volumetric reduction in disc volume and subsequent indirect decompression of lumbar nerve roots [35] are therapeutically beneficial when managing patients with this painful and disabling disease.

Ozone also enhances oxygenation and blood flow [33] to the damaged areas in the annulus and nucleus. It may support the metabolic needs of the disc cells, improve tissue healing, and stimulate tissue regeneration. Additional benefits are its antimicrobial properties, lowering the risk of discitis and infection of the surrounding structures, particularly when surgical or interventional treatment is

CHAPTER 9

Allogeneic Stem Cell Therapy for Painful Intermediate Lumbar Degenerative Discs

Álvaro Dowling¹, Juan Carlos Vera², Jorge Felipe Ramírez León^{3,4,5}, William Omar Contreras López⁶, Morgan P. Lorio⁷ and Kai-Uwe Lewandrowski^{8,9,10,*}

¹ Orthopaedic Spine Surgeon, Director of Endoscopic Spine Clinic, Santiago, Chile

² Universidad de Chile, Santiago, Chile

³ Minimally Invasive Spine Center, Bogotá, D.C., Colombia

⁴ Reina Sofía Clinic, Bogotá, D.C., Colombia

⁵ Fundación Universitaria Sanitas, Bogotá, D.C., Colombia

⁶ Clínica Foscal Internacional, Autopista Floridablanca - Girón, Km 7, Floridablanca, Santander, Colombia

⁷ Advanced Orthopedics, 499 East Central Parkway, Altamonte Springs, FL 32701, USA

⁸ Center for Advanced Spine Care of Southern Arizona and Surgical Institute of Tucson, Tucson, AZ, USA

⁹ Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá, D.C., Colombia

¹⁰ Department of Neurosurgery in the Video-Endoscopic Postgraduate Program at the Universidade Federal do Estado do Rio de Janeiro - UNIRIO, Rio de Janeiro, Brazil

Abstract: The management of mid-stage degenerative disc disease presenting with pain remains contentious, attributed in part to the scarcity of conclusive clinical trials. Allogeneic mesenchymal stem cells (MSCs), procured from donors, emerge as a viable alternative to autologous stem cell therapy. These MSCs are characterized by their accessibility and the streamlined administration process suitable for procedure-room settings, particularly for addressing discogenic lumbar pain. Within this manuscript, the authors delineate their proprietary protocol involving allogeneic MSC application, detailing the efficacy, safety, and clinical implications post-infusion into symptomatic lumbar intervertebral discs. Their clinical series encompassed 32 subjects, 14 females and 18 males, averaging 47.6 years of age, with a mean follow-up duration of 26.88 months. Two-year post-treatment evaluations revealed notable decrements in both ODI and VAS scores for lumbar pain. Evaluating Macnab outcomes, 11 participants (33.3%) showcased excellent results, 19 (57.6%) reported good outcomes, and a mere 3 (9.1%) indicated fair results. Notably, none necessitated supplementary interventions at

* **Corresponding author Kai-Uwe Lewandrowski:** Center for Advanced Spine Care of Southern Arizona and Surgical Institute of Tucson, Tucson, AZ, USA; Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá, D.C., Colombia and Department of Neurosurgery in the Video-Endoscopic Postgraduate Program at the Universidade Federal do Estado do Rio de Janeiro - UNIRIO, Rio de Janeiro, Brazil; E-mail: adowling@dws.cl

the MSC-treated disc level. Despite the study's constraints, such as its observational nature, potential selection and hindsight biases, and modest participant count, the authors' findings substantiate the potential of intradiscal allogeneic MSC injections in managing mid-stage painful degenerative disc afflictions. To fortify these preliminary insights, future research endeavors should encompass a more regimented structure, potentially incorporating a placebo cohort or a natural progression study group.

Keywords: Allogeneic, Mesenchymal stem cells, Low back pain, Degenerative intervertebral disc disease.

INTRODUCTION

The dawn of the 21st century heralded significant strides in biotechnology, ushering in transformative therapeutic modalities that have markedly elevated patient care and outcomes. Predominantly, regenerative medicine has spearheaded this metamorphosis, encompassing novel techniques like cell therapy, gene therapy, and tissue engineering [1 - 4]. Forefront interventions in this arena include the deployment of platelet-enriched plasma [5 - 8], stem cells [3, 9], and the derivatives procured from their culture. These interventions, in many cases, have not only ameliorated symptoms but also proffered potential cures [10 - 12].

A meticulous review by Sanapati *et al.* probed into the therapeutic efficacy of mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) for conditions including discogenic low back pain, radicular pain, and sacroiliac joint pain, among others [13]. The outcomes showcased a spectrum of evidentiary support for the therapeutic promise of MSCs and PRP for these pain manifestations.

In contemporary research, allogeneic stem cell transplantation has surfaced as a compelling counterpart to autologous bone marrow transplants [14 - 17]. Its preeminence is accentuated by its capacity to curtail functional discrepancies through the employment of multi-donor cell aggregates housed in a central repository. Notably, MSCs exhibit an inherent aptitude for allogeneic transplantation with a negligibly low rejection proclivity [18]. Within this discourse, the authors delineate their modus operandi for deploying allogeneic stem cell interventions for degenerative disc disease (DDD)-induced pain. The overarching endeavor is to interrogate the therapeutic safety profile of MSCs and their potential to mitigate chronic low back pain (CLBP) symptoms, thereby optimizing patient functionality. This exploration aims to set the stage for ensuing inquiries into the merits and safety considerations of allogeneic stem cell interventions for back pain and varying stages of DDD.

This chapter's focus is the safety appraisal of a solitary allogeneic MSC injection in a clinical setting, targeting a symptomatic lumbar disc, and concurrently

gauging the ensuing therapeutic ramifications in patients grappling with CLBP linked to moderate DDD.

Allogeneic Mesenchymal Stem Cells (MSCs)

The increase of allogeneic mesenchymal stem cells (MSCs) in regenerative medicine positions them as an attractive counterpart to autologous transplants. Sourced from external donors, these cells stand out due to their simplified procurement process, stellar safety record, and demonstrated efficacy in addressing myriad medical and musculoskeletal maladies. Typically extracted from bone marrow, peripheral blood, or umbilical cord blood, allogeneic MSCs present diminished risks associated with contamination, mutation, and graft rejection compared to their autologous counterparts. These multipotent cells, endowed with the ability for differentiation into diverse cell types and self-renewal, also exhibit pronounced immunomodulatory attributes, making them compelling candidates for managing inflammatory and autoimmune disorders. Advantages encompass expedited transplantation timelines, diminished infection risks, procedural complications, and lessened reliance on intensive immunosuppression.

One realm where the therapeutic potential of allogeneic stem cells shines is in addressing degenerative disc disease (DDD), a predominant contributor to chronic low back pain. DDD's etiology involves intervertebral disc degradation, precipitating disc herniation, spinal stenosis, and nerve entrapment. Conventional DDD interventions span medications, physical rehabilitative therapies, and surgical approaches, but their efficacy is oftentimes transient and fraught with potential risks. Research, such as the study by Pettine *et al.*, underscores the substantial efficacy and safety of MSCs in ameliorating discogenic pain and restoring function. Multiple investigations [19 - 24] corroborate the well-tolerated nature of these cells, with an absence of grave adverse outcomes, reinforcing their therapeutic promise in offering sustained respite from chronic lumbar discomfort.

Yet, navigating the therapeutic deployment of allogeneic stem cells is not devoid of challenges. Immune rejection [25], stemming from the recipient's immune defenses perceiving the introduced cells as alien, remains a concern [26]. Strategies to curb this include meticulous cell matching to the recipient's tissue. Notably, heavy immunosuppressive regimens are generally unnecessary. Nonetheless, an in-depth exploration into their clinical viability, safety contours, and economic competitiveness in juxtaposition to other regenerative modalities is imperative.

SUBJECT INDEX

A

Acid 63, 69, 83, 184, 186, 188
 hyaluronic 63, 69, 184, 186, 188
 lactic 83
 polyglycolic 63, 69
 Acidic ambience 19
 Activation 87, 89, 121, 127, 134
 immune system 134
 inflammatory 121
 Agents 23, 63, 91, 92, 130, 156, 166, 167, 174
 anti-inflammatory 167
 biocompatible 63
 chelating 91
 enzymatic 23, 92
 hemostatic 156
 inflammation-reducing 166
 stimulate vasculogenesis 130
 Aging 3, 4, 6, 7, 9, 12, 13, 20, 24, 57
 hastening 6
 Allogeneic 182, 186, 188
 progenitor cells (APCs) 186, 188
 transplantation 182
 Angiogenetic pathways 127
 Anterior cord syndrome 118
 Anti-inflammatory 45, 65, 166, 191
 cytokine 65
 drugs 45
 medications 166, 191
 Assessments 76, 99, 114, 117, 127, 148, 189,
 190
 electrophysiological 127
 reflexogenic 117
 Astrocytes 125, 130
 Atherosclerosis 7
 Augmentation 69, 127, 191
 aesthetic 191
 Autologous bone marrow 45, 182
 mesenchymal stem cells 45
 transplants 182
 Autologous stem cells 124
 Autophagy 34, 41, 42

inhibition 42

B

Balance 6, 87, 125, 166
 chemical 125
 emotional 6
 microenvironmental 125
 osmotic 166
 Biologically based polymers 67
 Biomechanics 18, 94
 spinal 94
 Biotechnology firms 4
 Blood-spinal cord barrier (BSCB) 112, 125
 Bone marrow 45, 90, 124, 126, 183
 -derived mesenchymal stem cells 126
 Brain-derived neurotrophic factor (BDNF)
 127
 Brown-Séguard syndrome 118
 Byproducts 83, 92, 170
 enzymatic 92
 metabolic 83

C

Capability 22, 23, 64, 65, 112, 122, 128, 129,
 173
 anti-inflammatory 173
 augmented cellular proliferation 23
 neuronal signal transduction 112
 thermogenic 22
 Cardiovascular problems 10
 Chondrocytes, hypertrophic 85
 Chondrogenesis 23
 Chromosomal aberrations 131
 Chronic lumbosacral pain 95
 Coagulopathy 149
 Collagen 18, 27, 41, 61, 63, 68, 69, 72, 84, 85,
 88
 fiber aggregations 18
 fibers 61
 fibrils 84, 88

Computed tomography (CT) 11, 60, 157, 166
 Conditions 6, 7, 10, 11, 36, 38, 40, 47, 83, 85,
 167, 182, 185, 187
 degenerative spinal 36
 lumbar disc 167
 neoplastic 187
 pro-inflammatory 6
 Contemporary therapeutic interventions 24
 COVID-19 pandemic 4
 Cross-linking 70
 agents 70
 methodologies 70
 Cryopreservation 186
 Cytokines 34, 44, 47, 58, 89, 91, 100, 112,
 121, 133, 166
 angiogenic 91
 pro-angiogenic 91
 proinflammatory 89, 112
 protease 166

D

Damage 6, 119, 120, 127
 metabolic 120
 neurostructural 119
 oxidative 6
 Deficits 85, 99, 114, 117, 147
 concomitant proteoglycan 85
 neurofunctional 117
 neuromotor 117
 sensory 99, 147
 Definitive immunophenotypic blueprint 26
 Deformities, anomalous 147
 Degeneration 3, 7, 8, 10, 19, 20, 28, 41, 71,
 83, 100, 120, 191
 painful 83
 process 19
 lumbar disc disease 191
 musculoskeletal diseases (DMDs) 7, 8, 10
 spine disease 3
 transformations 20
 Degradation, morphological 66
 Density, compromised bone mineral 99
 Deployment, therapeutic 183
 Devices, prosthetic 92
 Diseases 4, 7, 11
 age-related 4
 cardiovascular 4, 7
 Disorders 6, 37, 38, 60, 76, 83, 102, 170, 183
 autoimmune 183

degenerative 6
 emotional 170
 musculoskeletal 37, 38
 spinal 38, 83

E

Efferocytosis 25, 26
 Electromyography 127
 Embryonic stem cells (ESCs) 17, 122, 123,
 124, 134, 135, 137
 Endoscopic techniques 144, 148, 157, 161
 Enzymatic degradation 91

F

Factors 20, 98
 neurobiological 98
 neurotrophic 20
 Fat 16, 22
 abdominal 22
 oxidation 22
 Fetal bovine serum (FBS) 23, 185
 Fibers 18, 68
 electrospun 68
 Fibrin 63, 72
 polymerizing 72
 Fibrocartilage 18
 Fibromyalgia 170
 Fibrosarcoma 131
 Flow cytometry 186
 Function 21, 25, 83, 100, 110, 124, 125, 131,
 132, 149
 cellular metabolic 83
 neurological 131, 132
 Functional neural circuitry 129

G

Glial fibrillary acidic protein (GFAP) 127
 Gliotic processes 112
 Global 45
 mental health (GMH) 45
 physical health (GPH) 45
 Glycosaminoglycan proportions 18
 Glycosaminoglycans 63, 69, 75
 Graft versus host disease (GVHD) 187
 Gravitational forces 114, 115
 Growth 4, 6, 133, 191

anomalous bone 191
neuronal 133

H

Health 6, 7, 10, 11, 13, 35, 169
 mental 6
 metabolic diseases impacting disc 169
 spinal 13
Healthcare systems 1, 4, 13, 35
Heart disease 10
Heightened spinal stress 191
Hyaluronidase 92

I

Immunohistochemical analysis 127
Immunomodulatory 26, 45, 136
 treatments 136
Immunosuppressive strategies 131
Inflammatory 47, 89, 125, 133
 immune responses 89
 responses 47, 133
 signaling 125
Influence, synergistic anabolic 43
Insult 88, 100, 112, 119, 121
 direct traumatic 88
 initial 112
 primary 121
 thermal 100
Intervertebral disc 17, 27, 35, 36, 57, 83, 166,
 168, 191
 degeneration (IDD) 17, 27, 35, 36, 83, 166,
 191
 disorders 57
 volumetric analysis (IDVA) 168
Intradiscal cell therapy 43
Ischemic-hypoxic events 121

L

Labyrinthine pathways 70
Laser-assisted liposuction (LAL) 23
Lipogenesis 23
Lipolysis 22
Lumbar 17, 27, 35, 36, 44, 83, 95, 166, 167,
 168, 169, 191
 disc herniation (LDH) 44, 167, 168, 169
 spinal pathoanatomy 95
Lymphocytes 112

M

Magnetic resonance imaging (MRI) 11, 60,
 76, 89, 90, 94, 100, 102, 126, 127, 132,
 149, 185, 187, 188
 signal intensity 76, 102
Mechanical stresses 18, 75
Mediators, pro-inflammatory 41, 121
Medical device regulation (MDR) 70
Mesenchymal 16, 17, 20, 21, 23, 24, 25, 26,
 27, 43, 63, 69, 72, 126, 128, 129, 181,
 182, 183, 184, 185, 187, 192
 precursor cells (MPCs) 72, 184
 stem cell (MSCs) 16, 17, 20, 21, 23, 24, 25,
 26, 27, 63, 69, 126, 128, 129, 181, 182,
 183, 185, 187, 192
 stromal cells 43
Metabolic pathways 58
Metamorphosis 131, 182
 malignant cellular 131
Methodologies, biomaterial-centric 75
Motor 114, 115, 118, 128, 130
 deficits 115, 118
 function 114, 128
 function impairment 115
 functionality, ameliorating 130
MSC(s) 26, 27, 126, 129, 130, 136, 185
 embryonic-origin 129
 therapy 26, 27, 126, 129, 130, 136, 185
 transplantation 130, 136
 umbilical cord 126, 185
Musculoskeletal system 12
Myelin-associated glycoprotein 113
Myriad processes 26

N

Necrosis 121
Neoangiogenesis 87
Neoplastic 88, 110, 119
 degradation 88
Nerve 41, 87, 91, 95, 102, 120, 147, 149, 152,
 153
 basivertebral 41, 87, 91, 95
 damage 147
 enlargement 149
 root pathways 102
Neural 86, 100, 111, 113, 121, 122, 125, 131,
 132

damage 121
 fibrils 86
 pathways 100, 111, 113
 progenitor cells (NPCs) 122, 125, 131, 132
 Neurodegenerative processes 112
 Neurological deficits 110
 Neurons 111, 122, 125, 128, 129, 130
 mature 129
 sensory 111
 Neurophysiological systems 58
 NLRP3 inflammasome pathway 125
 Nucleus pulposus (NP) 16, 17, 18, 19, 20, 24,
 25, 27, 41, 42, 59, 60, 66, 68, 69, 73, 85,
 166
 dehydrating 166

O

Oligodendrocyte progenitor cells (OPCs) 122,
 131
 Ontogenesis 58, 102
 pathological 102
 Osteoarthritis 7, 12, 187
 degenerative 187
 Osteoblasts 20, 21, 24, 43
 Osteoclastic resorption 85
 Osteogenesis 23
 Osteointegration 75, 91, 92
 Oxidative stress 41

P

Pain 8, 9, 10, 11, 17, 18, 44, 45, 46, 47, 57,
 58, 165, 166, 167, 172, 174, 182, 185
 inflammatory 165
 radicular 182
 signaling pathways 167
 syndromes 11
 Pain management 11, 41, 44, 173
 conventional 173
 modalities 41
 surgical 11
 Platelet-rich plasma (PRP) 43, 44, 46, 93, 94,
 96, 165, 166, 167, 168, 170, 171, 173,
 174, 182
 treatment 96
 Porous silk fibroin 62
 Positron emission tomography (PET) 11
 Post 172, 173
 -intervention MRI assessments 173

 -procedure MRI scanning 172
 Power-assisted liposuction (PAL) 23
 Pro-inflammatory cytokines 129
 Proapoptotic 131
 mediator 131
 Proinflammatory agents 19

R

Radiculopathy 35, 168, 169, 187
 lumbar 168
 Ramifications, therapeutic 127, 183
 Randomized controlled trial (RCT) 46, 95, 97,
 134
 Reactive oxygen species (ROS) 41, 112
 Rejuvenation industry 2
 Release, neurotransmitter 121
 Repair implementations 60
 Reparative effort 86
 Responses 20, 26, 122, 125, 168, 169, 184,
 190
 immunological 122
 pathophysiological pain 20
 Restoration, dermatological 20
 Rheumatoid arthritis (RA) 148
 RNA interference 42

S

Sarcopenia 7, 12
 Scrutiny, microscopic 88
 Severity, degenerative 94
 Sexual dysfunction 119
 Silk polypeptide 67
 Skeletogenesis 85
 Sleep optimization 13
 Somatically-derived stem cells 124
 Spinal 95, 100
 arthropathy 100
 canal narrowing, symptomatic 95
 regenerative processes 95
 Spinal cord 76, 100, 110, 111, 117, 118, 119,
 121, 125, 127, 128, 129, 134, 136
 continuity 119
 damage 128
 hemisection defects 129
 insults 100
 lesions 117, 134
 regeneration 110, 136
 Spinal cord injury 126, 132, 133, 135

acute 135
cervical 126, 133
chronic 132
Spine care, traditional surgical 168
Spondylodesis 74
Spondylolisthesis 169, 187
Stem cell(s) 21, 72, 127, 128, 129, 130, 132, 133, 135
marrow-derived 72
marrow-derived mesenchymal 21, 128, 129, 132, 133
neural 127, 128, 130
research 135
Stenosis 36, 169, 183, 187
bony 169
spinal 183
Sterile 157, 158
dressing, dry 157
Steroid injections 146
Superficial palmar arch (SPA) 6, 148, 153
Surgery 3, 43, 143, 146, 147, 153, 156, 160, 161
orthopedic 43
Surgical 35, 60, 70, 144, 145, 146, 147, 153, 157, 162
instruments 144, 157
interventions 35, 60, 70, 145, 146, 147
techniques 153, 162
treatment 145
Sustainable frameworks 135
Syndromes 7, 117, 118, 119, 146, 173
chronic regional pain 146
metabolic 7
Synergistic stem cell amalgamations 137

T

Techniques 13, 34, 60, 150
genetic 34
hybrid 60
invasive 150
stress management 13
Tendogenesis 23
Tendon repair 43
Tenosynovitis 149
Tenotomy scissors 155
Tensile stresses 73
Therapies, hormone 99

Thermogenic pathway 22
Third common digital nerve (TCDN) 152
Tissue 34, 47, 87, 124
homeostasis 87, 124
recuperation 34
regeneration 34, 47
Transforaminal endoscopic lumbar
discectomy (TELD) 44
Treatment cohorts 184
Tumor necrosis factor (TNF) 19
Tumorigenicity 131

U

Ultrasound machine 156

V

Vascular endothelial growth factor (VEGF)
23, 91, 130

W

Wellness 4, 5, 6, 11
economy 4, 5, 6
optimal 11
Wound repair 20, 23
augmenting tissue 23